100 results on '"Ilhan Satman"'
Search Results
2. Clinical Manifestations and Biomarkers of the Maturity-Onset Diabetes of the Young
- Author
-
İlhan Satman
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Published
- 2023
- Full Text
- View/download PDF
3. Obstacles and expectations of rare disease patients and their families in Türkiye: ISTisNA project survey results
- Author
-
Ozden Hatirnaz Ng, Ilayda Sahin, Yucel Erbilgin, Ozkan Ozdemir, Emrah Yucesan, Nazli Erturk, Merve Yemenici, Ozlem Akgun Dogan, Sibel Aylin Ugur Iseri, Ilhan Satman, Yasemin Alanay, and Ugur Ozbek
- Subjects
rare disease ,survey ,Türkiye ,ISTisNA ,patient expectations ,Public aspects of medicine ,RA1-1270 - Abstract
Rare disease patients constitute a significant part of the healthcare system of all countries. However, the information on the experiences during disease processes and daily life of rare disease patients is still limited. So far, there is a small number of studies conducted in Türkiye, and they mainly cover specific issues like education or anxiety. Here we present a comprehensive survey analysis conducted among the patients and their families within the scope of the Istanbul Solution Platform for Undiagnosed and Rare Diseases-ISTisNA project. A total of 498 individuals responded to the survey, and 58% of the participants answered all questions. The majority of the patients were in the age range of 1–10 years (44.7%), and 91% of all the patients had a precise diagnosis. The diagnosis rate in the first 6 months was 69%, and almost 10% of the patients remained undiagnosed. The mothers were the primary caregivers (72%). Nearly 30% of the caregivers had to quit their jobs and 25% of the patients (0–18 years) had to leave school. Accessing physicians with relevant specialization and reaching treatments/medications/supplements were the two main obstacles the participants mentioned, with a frequency of 81% and 73%, respectively. Around 50% of participants noted that they commonly faced difficulties at work/school and in their social lives. The highest expectation or priority was the establishment of rare disease-specific diagnosis and treatment centers, accurate and detailed information on diseases in the Turkish language, and easy access to physicians, treatments, and supportive therapies. To the best of our knowledge, this is the most comprehensive survey conducted on the rare disease community in Türkiye. These results show that regardless of the country, the individuals affected by rare diseases and their families have similar problems and expectations. On the other hand, regional and country-specific issues are still in the line to be solved. These studies can provide a deeper insight into rare diseases and guide the activities of Türkiye's national rare disease action plan.
- Published
- 2023
- Full Text
- View/download PDF
4. Determinants and Perceptions of Tobacco Use Habits of University Students: An Example from Health Services School Students in Istanbul
- Author
-
Özden GÜDÜK, Selda SELİMOĞLU NAMOĞLU, Merve YEMENİCİ, Nazlı ERTÜRK, Kazım Yalçın ARĞA, Yeliz DOĞAN MERİH, and İlhan SATMAN
- Subjects
behavior ,waterpipe (narghile) ,cigarettes ,tobacco ,tobacco products ,university student ,Nursing ,RT1-120 - Abstract
Aim: To examine tobacco and tobacco use behaviors of the students of Health Vocational School and to reveal the determining factors on this behavior. Methods: This research was carried out in Medipol University Health Services Vocational School. A structured questionnaire with a total of 26 questions was applied to 307 students face to face. The data were analyzed using the SPSS 23 program by Pearson chi-square test and binary logistic regression model. Before the study, approval was obtained from the Medipol University Non-Invasive Research Ethics Committee. Results: The survey data showed that 32.6% of the students used tobacco products (mainly cigarettes), the frequency of smoking habit of male students was higher, they started smoking at an earlier age and the amount of daily consumption was higher. In the development of smoking behavior, it has been observed that having the belief of “smoking is harmful for health” has a decreasing effect, whereas smoking of frequently seen friends has an increasing effect. When the first and last years of university education are compared, it is found that the number of students who smoke increases over time. Conclusion: Compared to previous studies, smoking and waterpipe use are increased among Health Vocational School students in our society. In this increase, gender, peer influence, curiosity, interest, stress, and cultural characteristics come to the front. For this reason, it is important to consider these issues in policies to combat tobacco products.
- Published
- 2021
- Full Text
- View/download PDF
5. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
- Author
-
Fahri Bayram, Alper Sonmez, Cem Haymana, Tevfik Sabuncu, Oguzhan Sitki Dizdar, Eren Gurkan, Ayse Kargili Carlioglu, Kemal Agbaht, Didem Ozdemir, Ibrahim Demirci, Cem Barcin, Serpil Salman, Tamer Tetiker, Mustafa Kemal Balci, Nur Kebapci, Canan Ersoy, Volkan Yumuk, Peter P. Toth, Ilhan Satman, and TEMD Study Group
- Subjects
Dyslipidemia ,Type 2 diabetes mellitus ,Lipid-lowering treatments ,Physicians’ attitudes ,Low-density lipoprotein cholesterol target attainment ,Statin cessation ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians’ attitudes on the treatment of diabetic dyslipidemia were also examined. Methods A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59–0.83). Conclusions Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM.
- Published
- 2020
- Full Text
- View/download PDF
6. Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study)
- Author
-
Alper Sonmez, Volkan Yumuk, Cem Haymana, Ibrahim Demirci, Cem Barcin, Sinem Kıyıcı, Sibel Güldiken, Gonca Örük, Basak Ozgen Saydam, Süleyman Baldane, Faruk Kutlutürk, Ferit Kerim Küçükler, Oğuzhan Deyneli, Berrin Çetinarslan, Tevfik Sabuncu, Fahri Bayram, and Ilhan Satman
- Subjects
Obesity ,Type 2 diabetes ,HbA1c ,Blood pressure ,Lipid metabolism ,Nutrition. Foods and food supply ,TX341-641 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Background: Obesity is the main obstacle for metabolic control in patients with type 2 diabetes. Turkey has the highest prevalence of obesity and type 2 diabetes in Europe. The effect of obesity on the metabolic control, and the macro- and microvascular complications of patients are not apparent. Objectives: This nationwide survey aimed to investigate the prevalence of overweight and obesity among patients with type 2 diabetes and to search for the impact of obesity on the metabolic control of these patients. We also investigated the independent associates of obesity in patients with type 2 diabetes. Methods: We consecutively enrolled patients who were under follow-up for at least 1 year in 69 tertiary healthcare units in 37 cities. The demographic, anthropometric, and clinical data including medications were recorded. Patients were excluded if they were pregnant, younger than 18 years, had decompensated liver disease, psychiatric disorders interfering with cognition or compliance, had bariatric surgery, or were undergoing renal replacement therapy. Results: Only 10% of patients with type 2 diabetes (n = 4,648) had normal body mass indexes (BMI), while the others were affected by overweight (31%) or obesity (59%). Women had a significantly higher prevalence of obesity (53.4 vs. 40%) and severe obesity (16.6 vs. 3.3%). Significant associations were present between high BMI levels and lower education levels, intake of insulin, antihypertensives and statins, poor metabolic control, or the presence of microvascular complications. Age, gender, level of education, smoking, and physical inactivity were the independent associates of obesity in patients with type 2 diabetes. Conclusion: The TEMD Obesity Study shows that obesity is a major determinant of the poor metabolic control in patients with type 2 diabetes. These results underline the importance of prevention and management of obesity to improve health care in patients with type 2 diabetes. Also, the results point out the independent sociodemographic and clinical associates of obesity, which should be the prior targets to overcome, in the national fight with obesity.
- Published
- 2019
- Full Text
- View/download PDF
7. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
- Author
-
Rafael Gabriel, Nisa Boukichou Abdelkader, Tania Acosta, Aleksandra Gilis-Januszewska, Ricardo Gómez-Huelgas, Konstantinos Makrilakis, Zdravko Kamenov, Bernhard Paulweber, Ilhan Satman, Predrag Djordjevic, Abdullah Alkandari, Asimina Mitrakou, Nebojsa Lalic, Stephen Colagiuri, Jaana Lindström, Jesús Egido, Andrea Natali, J Carlos Pastor, Yvonne Teuschl, Marcus Lind, Luis Silva, Ruy López-Ridaura, Jaakko Tuomilehto, and e-PREDICE Consortium
- Subjects
Medicine ,Science - Abstract
OBJECTIVES:To assess the effects of early management of hyperglycaemia with antidiabetic drugs plus lifestyle intervention compared with lifestyle alone, on microvascular function in adults with pre-diabetes. METHODS:Trial design: International, multicenter, randomised, partially double-blind, placebo-controlled, clinical trial. PARTICIPANTS:Males and females aged 45-74 years with IFG, IGT or IFG+IGT, recruited from primary care centres in Australia, Austria, Bulgaria, Greece, Kuwait, Poland, Serbia, Spain and Turkey. INTERVENTION:Participants were randomized to placebo; metformin 1.700 mg/day; linagliptin 5 mg/day or fixed-dose combination of linagliptin/metformin. All patients were enrolled in a lifestyle intervention program (diet and physical activity). Drug intervention will last 2 years. Primary Outcome: composite end-point of diabetic retinopathy estimated by the Early Treatment Diabetic Retinopathy Study Score, urinary albumin to creatinine ratio, and skin conductance in feet estimated by the sudomotor index. Secondary outcomes in a subsample include insulin sensitivity, beta-cell function, biomarkers of inflammation and fatty liver disease, quality of life, cognitive function, depressive symptoms and endothelial function. RESULTS:One thousand three hundred ninety one individuals with hyperglycaemia were assessed for eligibility, 424 excluded after screening, 967 allocated to placebo, metformin, linagliptin or to fixed-dose combination of metformin + linagliptin. A total of 809 people (91.1%) accepted and initiated the assigned treatment. Study sample after randomization was well balanced among the four groups. No statistical differences for the main risk factors analysed were observed between those accepting or rejecting treatment initiation. At baseline prevalence of diabetic retinopathy was 4.2%, severe neuropathy 5.3% and nephropathy 5.7%. CONCLUSIONS:ePREDICE is the first -randomized clinical trial with the aim to assess effects of different interventions (lifestyle and pharmacological) on microvascular function in people with pre-diabetes. The trial will provide novel data on lifestyle modification combined with glucose lowering drugs for the prevention of early microvascular complications and diabetes. REGISTRATION:- ClinicalTrials.Gov Identifier: NCT03222765 - EUDRACT Registry Number: 2013-000418-39.
- Published
- 2020
- Full Text
- View/download PDF
8. Temporal changes in the epidemiology of diabetes mellitus in Turkey: A systematic review and meta-analysis
- Author
-
Mehmet Birhan Yılmaz, Mustafa Kılıçkap, Adnan Abacı, Cem Barçın, Fahri Bayram, Doruk Karaaslan, Hüseyin Göksülük, Meral Kayıkçıoğlu, Necla Özer, Gültekin Süleymanlar, Mahmut Şahin, Lale Tokgözoğlu, and İlhan Satman
- Subjects
diabetes mellitus ,epidemiology ,meta analysis ,prevalence. ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: Diabetes mellitus (DM) is a serious public health problem. Despite various epidemiological studies reporting prevalence of DM in Turkey, there is no meta-analysis or systematic review evaluating these studies as a whole and assessing temporal changes in the prevalence of DM. In this meta-analysis, the studies that have been conducted in the last 15 years and which provide information on the prevalence of DM in our country are examined. Methods: Epidemiological studies on cardiovascular risk factors in adult Turkish population that had been conducted within the last 15 years and having the capacity of either representating or potentially representing the country, were searched through Ovid, Medline and Web of Science Core Collection the Turkish Academic Network and Information Center (ULAKBIM) databases. Additionally, websites of Ministry of Health and related societies were investigated for additional studies. Random effects model was used in meta-analysis of low bias risk studies. Meta-regression was performed to evaluate the temporal change in DM prevalence. Results: There were 8 studies which provided information with regard to DM prevalence (n=84656). Four of these studies (n=56853) had low bias risk and four had high bias risk (n=27803). When compared with low bias risk studies, those with high bias risk had very large variation of DM prevalence (between 4% to 15%). Meta-analysis of the low bias risk group yielded a crude DM prevalence of 13.5% (95% CI: 11.6-15.5%) in the whole group, 14.2% (95% CI: 12.3-16.2%) in females, 12.6% (95% CI: 10.5-14.9%) in males. In meta-regression analysis of low bias risk group, mean age difference among the studies and the time period in which the study was undertaken were partially able to explain the inter-study heterogeneity (R2 values were 52% and 78%). Conclusion: This meta-analysis shows that DM is a highly prevalent public health problem in our country. Contrary to studies, which compare the recent studies with previous ones and report an increasing prevalence of DM, the present meta-analysis–despite its limitations-provides findings that the temporal increase of DM prevalence is at least paused over time. This situation underlines the need for new studies.
- Published
- 2018
- Full Text
- View/download PDF
9. Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
- Author
-
Lawrence A. Leiter, Marina V. Shestakova, and Ilhan Satman
- Subjects
Type 2 diabetes ,Gliclazide ,Glycemic control ,Tolerability ,Real-world ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment. Methods A total of 7170 participants from eight countries, age ≥ 35 years with HbA1c ≥ 7.5% and not treated with insulin, were prescribed 30–120 mg of gliclazide MR 60 mg once daily. HbA1c goals were individualized and dosing uptitrated, as required, over the 6-month long study. In this post hoc subanalysis, efficacy endpoints were analyzed according to stratified baseline HbA1c levels, weight and glucose-lowering regimens. Episodes of hypoglycemia requiring assistance were documented. Results At baseline, mean age was 58.9 years, HbA1c 8.8%, BMI 30.1 kg/m2, and diabetes duration 5.1 years. At study end, clinically significant HbA1c improvements (mean change − 1.78%) were noted across all baseline HbA1c strata (> 7.0 to ≤ 8.0%, > 8.0 to ≤ 9.0%, > 9.0 to ≤ 10.0%, and > 10.0%), BMI classifications (18.5 to
- Published
- 2018
- Full Text
- View/download PDF
10. Could the ENPP1 p.D85H Mutation be Associated with Hypophosphatemic Rickets?
- Author
-
Ender COŞKUNPINAR, Sakin TEKİN, Şükrü PALANDUZ, Hakan AVCI, Kıvanç CEFLE, N. Ozan TİRYAKİOĞLU, Ayşe KUBAT ÜZÜM, Refik TANAKOL, and İlhan SATMAN
- Subjects
Hypophosphatemic rickets ,hearing loss ,ENPP1 ,mutation ,Medicine (General) ,R5-920 - Abstract
Objective:A 35-year-old Turkish male patient was referred to us with a year-long history of joint paint and congenital hearing loss. Family history revealed more family members with hearing loss without paraneoplastic syndrome. These findings led us to investigate the genetic alterations associated with familial hypophosphatemia, which revealed an ENPP1 mutation.Methods:Serum samples were obtained after 12-hour fasting. The mutation analysis was performed using previously described primers. Total RNA was isolated from blood samples using Qiagen Total RNA extraction mini kit. cDNA samples were amplified using polymerase chain reaction (PCR), and these PCR products were purified using commercial kits. Following amplification and purification, the PCR products were sequenced.Results:The patient was found to have hypophosphatemia, a high level of PTH, and elevated plasma alkaline phosphatase. Sequencing results revealed an ENPP1 p.D85H mutation.Conclusion:We present the identification of an inactivating mutation in the ectonucleotide pyrophosphatase/phosphodiesterase-1. The substituted amino acid residue is highly conserved in ENPP1. At present, we have no further explanation, but our results suggest that ENPP1 p.D85H mutation may be associated with hypophosphatemic rickets accompanied by hearing loss.
- Published
- 2018
- Full Text
- View/download PDF
11. Fine-scale haplotype mapping of MUT, AACS, SLC6A15 and PRKCA genes indicates association with insulin resistance of metabolic syndrome and relationship with branched chain amino acid metabolism or regulation.
- Author
-
Sara Haydar, Florin Grigorescu, Mădălina Vintilă, Yannick Cogne, Corinne Lautier, Yildiz Tutuncu, Jean Frederic Brun, Jean Marie Robine, Michel Pugeat, Christophe Normand, Patrick Poucheret, Monica Livia Gheorghiu, Carmen Georgescu, Corin Badiu, Nicoleta Băculescu, Eric Renard, Dorina Ylli, Stephanie Badiou, Thibault Sutra, Jean Paul Cristol, Jacques Mercier, Ramon Gomis, Josep Maria Macias, Serghey Litvinov, Elza Khusnutdinova, Catalina Poiana, Renato Pasquali, Davide Lauro, Giorgio Sesti, Sabrina Prudente, Vincenzo Trischitta, Agathocles Tsatsoulis, Sonia Abdelhak, Abdelhamid Barakat, Akila Zenati, Agron Ylli, Ilhan Satman, Timo Kanninen, Yves Rinato, and Sasa Missoni
- Subjects
Medicine ,Science - Abstract
Branched chain amino acids (BCAA) are essential elements of the human diet, which display increased plasma levels in obesity and regained particular interest as potential biomarkers for development of diabetes. To define determinants of insulin resistance (IR) we investigated 73 genes involved in BCAA metabolism or regulation by fine-scale haplotype mapping in two European populations with metabolic syndrome. French and Romanians (n = 465) were genotyped for SNPs (Affymetrix) and enriched by imputation (BEAGLE 4.1) at 1000 genome project density. Initial association hits detected by sliding window were refined (HAPLOVIEW 3.1 and PHASE 2.1) and correlated to homeostasis model assessment (HOMAIR) index, in vivo insulin sensitivity (SI) and BCAA plasma levels (ANOVA). Four genomic regions were associated with IR located downstream of MUT, AACS, SLC6A15 and PRKCA genes (P between 9.3 and 3.7 x 10-5). Inferred haplotypes up to 13 SNPs length were associated with IR (e.g. MUT gene with P < 4.9 x 10-5; Bonferroni 1.3 x 10-3) and synergistic to HOMAIR. SNPs in the same regions were also associated with one order of magnitude lower P values (e.g. rs20167284 in the MUT gene with P < 1.27 x 10-4) and replicated in Mediterranean samples (n = 832). In French, influential haplotypes (OR > 2.0) were correlated with in vivo insulin sensitivity (1/SI) except for SLC6A15 gene. Association of these genes with BCAA levels was variable, but influential haplotypes confirmed implication of MUT from BCAA metabolism as well as a role of regulatory genes (AACS and PRKCA) and suggested potential changes in transcriptional activity. These data drive attention towards new regulatory regions involved in IR in relation with BCAA and show the ability of haplotypes in phased DNA to detect signals complimentary to SNPs, which may be useful in designing genetic markers for clinical applications in ethnic populations.
- Published
- 2019
- Full Text
- View/download PDF
12. A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria
- Author
-
Yildiz Tutuncu, Ilhan Satman, Selda Celik, Nevin Dinccag, Kubilay Karsidag, Aysegul Telci, Sema Genc, Halim Issever, Jaakko Tuomilehto, and Beyhan Omer
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) have been used to diagnose new-onset diabetes mellitus (DM) in order to simplify the diagnostic tests compared with the 2-hour oral glucose tolerance test (OGTT; 2-hPG). We aimed to identify optimal cut-off points of high sensitive C-reactive protein (hs-CRP) in new-onset DM people based on FPG, 2-hPG, or HbA1c methods. Data derived from recent population-based survey in Turkey (TURDEP-II). The study included 26,499 adult people (63% women, response rate 85%). The mean serum concentration of hs-CRP in women was higher than in men (p
- Published
- 2016
- Full Text
- View/download PDF
13. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey.
- Author
-
Levent Akın, Bérengère Macabéo, Zafer Caliskan, Serdar Altinel, and Ilhan Satman
- Subjects
Medicine ,Science - Abstract
In Turkey, the prevalence of diabetes is high but the influenza vaccination coverage rate (VCR) is low (9.1% in 2014), despite vaccination being recommended and reimbursed. This study evaluated the cost-effectiveness of increasing the influenza VCR of adults with type 2 diabetes in Turkey to 20%.A decision-analytic model was adapted to Turkey using data derived from published sources. Direct medical costs and indirect costs due to productivity loss were included in the societal perspective. The time horizon was set at 1 year to reflect the seasonality of influenza.Increasing the VCR for adults with type 2 diabetes to 20% is predicted to avert an additional 19,777 influenza cases, 2376 hospitalizations, and 236 deaths. Associated influenza costs avoided were estimated at more than 8.3 million Turkish Lira (TRY), while the cost of vaccination would be more than TRY 8.4 million. The incremental cost-effectiveness ratio was estimated at TRY 64/quality-adjusted life years, which is below the per capita gross domestic product of TRY 21,511 and therefore very cost-effective according to World Health Organization guidelines. Factors most influencing the incremental cost-effectiveness ratio were the excess hospitalization rate, inpatient cost, vaccine effectiveness against hospitalization, and influenza attack rate. Increasing the VCR to >20% was also estimated to be very cost-effective.Increasing the VCR for adults with type 2 diabetes in Turkey to ≥20% would be very cost-effective.
- Published
- 2016
- Full Text
- View/download PDF
14. Branched-Chain Amino Acid Database Integrated in MEDIPAD Software as a Tool for Nutritional Investigation of Mediterranean Populations
- Author
-
Sara Haydar, Thomas Paillot, Christophe Fagot, Yannick Cogne, Athanasios Fountas, Yildiz Tutuncu, Madalina Vintila, Agathocles Tsatsoulis, Pham Thanh Chi, Patrick Garandeau, Dan Chetea, Corin Badiu, Monica Gheorghiu, Dorina Ylli, Corinne Lautier, Morana Jarec, Louis Monnier, Christophe Normand, Jelena Šarac, Abdelhamid Barakat, Sasa Missoni, Michel Pugeat, Patrick Poucheret, Felicia Hanzu, Ramon Gomis, Josep Maria Macias, Serghey Litvinov, Elza Khusnutdinova, Catalina Poiana, Renato Pasquali, Davide Lauro, Giorgio Sesti, Vincenzo Trischitta, Sonia Abdelhak, Akila Zenati, Agron Ylli, Ilhan Satman, Timo Kanninen, Yves Rinato, and Florin Grigorescu
- Subjects
BCAA ,24-h dietary recall ,computer technology ,nutrition ,dietary assessment ,insulin resistance ,Mediterranean ,web-based recalls ,metabolic syndrome ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Branched-chained amino acids (BCAA) are essential dietary components for humans and can act as potential biomarkers for diabetes development. To efficiently estimate dietary intake, we developed a BCAA database for 1331 food items found in the French Centre d’Information sur la Qualité des Aliments (CIQUAL) food table by compiling BCAA content from international tables, published measurements, or by food similarity as well as by calculating 267 items from Greek, Turkish, Romanian, and Moroccan mixed dishes. The database embedded in MEDIPAD software capable of registering 24 h of dietary recalls (24HDR) with clinical and genetic data was evaluated based on archived 24HDR of the Saint Pierre Institute (France) from 2957 subjects, which indicated a BCAA content up to 4.2 g/100 g of food and differences among normal weight and obese subjects across BCAA quartiles. We also evaluated the database of 119 interviews of Romanians, Turkish and Albanians in Greece (27–65 years) during the MEDIGENE program, which indicated mean BCAA intake of 13.84 and 12.91 g/day in males and females, respectively, comparable to other studies. The MEDIPAD is user-friendly, multilingual, and secure software and with the BCAA database is suitable for conducting nutritional assessment in the Mediterranean area with particular facilities for food administration.
- Published
- 2018
- Full Text
- View/download PDF
15. Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
- Author
-
Ilhan Satman, Hayley Bennett, Candeger Yilmaz, Sazi Imamoglu, Goksun Ayvaz, Abdurrahman Comlekci, Demet Ozkaya, and Toros Sahin
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
**Background:** Type 2 diabetes mellitus (T2DM) poses a significant burden on population well being and healthcare expenditure in Turkey, with disease prevalence continuing to increase. Insulin treatment is necessary for patients failing to achieve glycaemic control with lifestyle modification or oral antidiabetic drugs. While neutral protamin Hagedorn (NPH) insulin has been traditionally prescribed for insulin introduction, insulin glargine has been shown to reduce glycated hemoglobin (HbA1c) with a more favourable hypoglycaemic profile. **Objective:** To evaluate the cost-effectiveness of insulin glargine compared to NPH insulin in patients with T2DM in Turkey, from a Social Security Institution perspective. **Methods:** A previously published discrete event simulation model of T2DM progression was utilised to characterise the cost-effectiveness of insulin glargine in a Turkish population given the benefits observed in clinical practice. Improvements in glycaemic control have been incorporated using data from The Health Improvement Network (THIN) database in the United Kingdom, combined with meta-regression results describing the relationship between hypoglycaemia and glycaemic control. Outcomes were evaluated over a 40-year horizon, and costs and benefits discounted at an annual rate of 3.5%. Results are reported in Turksih lira (TL), 2012. **Results:** Over a lifetime, the Incremental Cost-effectiveness Ratio (ICER) of insulin glargine compared to NPH was 40,101 TL per Quality-adjusted Life Year (QALY). Almost 52 hypoglycaemic events per patient were avoided with the use of insulin glargine compared to NPH, at an incremental lifetime cost of 7,140 TL per patient. The cost-effectiveness of insulin glargine is reduced when modelling only those benefits considered in the trial setting, while the cost-effectiveness profile can be expected to further improve in patients with higher HbA1c levels at baseline. **Conclusion:** It is difficult to interpret the results of modelling as there is no official cost-effectiveness threshold in Turkey. However, the results may be evaluated using thresholds derived according to methodology proposed by the World Health Organisation (WHO). Insulin glargine is expected to be costeffective compared to NPH insulin, with an ICER below three times the estimated gross domestic product (GDP) per capita; 56,850 TL.
- Published
- 2013
- Full Text
- View/download PDF
16. Developing a diabetes management system integrated with salivary glucose sensors
- Author
-
Ilhan Satman, Sadullah Ozturk, Ulvi Baspinar, Adem Karahoca, Zeki Candan, Murat Gezer, Calikoglu B. Fulya, Ayse Palanduz, Ayse Kubat Uzum, Hulya Hacisahinogullari, Aydin A. Fatih, Denizeri Guy S. Banu, Baris Ozgen, Huseyin Keskin, Elif Mert, Deniz Sakarya, Imren Ergun, Yasin Koker, Oncul M. Oral, and SATMAN İ., ÖZTÜRK S., BAŞPINAR U., KARAHOCA A., CANDAN Z., GEZER M., ÇALIKOĞLU B. F., PALANDUZ A., KUBAT ÜZÜM A., HACİŞAHİNOĞULLARI H., et al.
- Subjects
General Medicine - Published
- 2023
17. Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial
- Author
-
Beyza Eliuz Tipici, Ender Coskunpinar, Derya Altunkanat, Penbe Cagatay, Beyhan Omer, Sukru Palanduz, Ilhan Satman, and Ferihan Aral
- Subjects
Type 2 Diabetes Mellitus ,Nutrition and Dietetics ,Mucin ,Gene Expression ,Medicine (miscellaneous) ,Lactobacillus GG ,Probiotic - Abstract
Purpose Recent studies indicate that dysbiosis of gut microbiota and low-grade infammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the efects of Lactobacillus GG on glycemic control, lipid profle, infammatory parameters, and some gene expression levels in individuals with T2DM. Methods In a randomized, placebo-controlled trial, 34 women, aged 30–60 years with T2DM consumed daily probiotics or placebo for 8 weeks. The probiotic group consumed 10× 109 Cfu/day Lactobacillus rhamnosus GG ATCC 53,103 (LGG), approved by the TR Ministry of Food, Agriculture, and Livestock. Anthropometric measurements, food diary, fasting blood, and fecal samples were taken at baseline and post-treatment. Results Fasting blood glucose was signifcantly decreased in probiotic (p=0.049) and placebo (p=0.028), but there was no diference between the groups. In the probiotic group, no signifcant diference was observed in HbA1c, fructosamine, lipid profle, and infammatory variables compared to baseline. In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p=0.046 and p=0.008, respectively) at posttreatment. Meanwhile, there was no signifcant change in any of the gene expressions in the placebo group. There was no signifcant diference in energy, protein, dietary fber, and cholesterol intakes between placebo and probiotic groups during the study. However, daily fat intake (p=0.003), body weight (p=0.014), and body fat (p=0.015) in the probiotic group were signifcantly decreased. Conclusion In this study, the efects of a single probiotic strain were investigated for 8 weeks. At the end of the study, although there was no fnding that clearly refected on the glycemic parameters of T2DM, its benefcial efects on the expression of mucin genes, which are responsible for weight loss and protection of intestinal barrier functions, cannot be denied. Further studies are needed to reveal the importance of these fndings. Clinical trial registration ID: NCT05066152, October 4, 2021 retrospectively registered in ClinicalTrials.gov PRS web site.
- Published
- 2023
18. Prediabetes and diabetes: main characteristics
- Author
-
Ilhan Satman
- Subjects
Internal Medicine - Published
- 2023
19. No association of Gaucher disease with COVID‐19‐related outcomes: a nationwide cohort study
- Author
-
Ibrahim Demirci, Tevfik Demir, Selcuk Dagdelen, Cem Haymana, Ilker Tasci, Aysegul Atmaca, Derun Ertugrul, Naim Ata, Mustafa Sahin, Serpil Salman, Ibrahim Sahin, Rifat Emral, Ugur Unluturk, Erman Cakal, Osman Celik, Murat Caglayan, Ilhan Satman, and Alper Sonmez
- Subjects
Cohort Studies ,Hospitalization ,Intensive Care Units ,Gaucher Disease ,Diabetes Mellitus, Type 2 ,SARS-CoV-2 ,Internal Medicine ,COVID-19 ,Humans ,Pandemics ,Retrospective Studies - Abstract
Background It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID-19 pandemic. However, when the subject is rare metabolic diseases, there are not enough data in the literature. Aim To investigate the course of COVID-19 among patients with Gaucher disease (GD), the most common lysosomal storage disease. Methods Based on the National Health System data, a retrospective cohort of patients with confirmed (polymerase chain reactionpositive) COVID-19 infection (n = 149 618) was investigated. The adverse outcomes between patients with GD (n = 39) and those without GD (n = 149 579) were compared with crude and propensity score-matched (PSM) groups. The outcomes were hospitalisation, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality. Results The patients with GD were significantly older and had a higher frequency of hypertension (HT), Type 2 diabetes mellitus (T2DM), dyslipidaemia, asthma or chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, heart failure and cancer. Although hospitalisation rates in Gaucher patients were found to be higher in crude analyses, the PSM models (model 1, age and gender matched; model 2, matched for age, gender, HT, T2DM and cancer) revealed no difference for the outcomes between patients with GD and the general population. According to multivariate regression analyses, having a diagnosis of GD was not a significant predictor for hospitalisation (P = 0.241), ICU admission/mechanical ventilation (P = 0.403) or mortality (P = 0.231). Conclusion According to our national data, SARS-CoV-2 infection in patients with GD does not have a more severe course than the normal population.
- Published
- 2022
20. Technology Use In Home Health Servıces
- Author
-
Yeliz DOĞAN MERİH, Nazlı ERTÜRK, Merve YEMENİCİ, and İlhan SATMAN
- Abstract
Evde sağlık hizmetleri, yatağa bağımlı hastalar, çeşitli kronik hastalıklar ya da ameliyat sonrası ihtiyaçları nedeniyle sağlık kuruluşuna ulaşımda zorluklar yaşayan hastalara ev ortamında muayene, tetkik, tedavi ve rehabilitasyon hizmetlerinin profesyonel bir sağlık ekibi tarafından verilmesidir. Bilimsel ve teknolojik atılımlar, sosyal hakların gelişmesi ve yaygınlaşması, uzun süreli kurumsal bakım hizmetlerindeki yetersizlikler ve sağlık hizmetleri harcamalarında artan maliyetler evde sağlık hizmetlerini gündeme taşıyan faktörler arasında yer almaktadır. Son yıllarda teknolojide gelişmeler, tanı ve tedavi hizmetlerinin sunum şekline ve kalitesine etkileriyle evde sağlık hizmetlerinde önemli gelişmelere sebep olmuştur. Medikal cihazlar arasındaki iletişim, yapay zekâ uygulamaları, karar destek sistemleri, tele-sağlık, giyilebilir teknolojiler, güvenli ev teknolojileri, bakım robotları, büyük veri, nesnelerin interneti, sanal gerçeklik evde sağlık hizmetlerinin inovatif yaklaşımları arasında yer almaktadır. Bu yenilikçi yaklaşımlar sayesinde, kaynakların çok kısıtlı olduğu evde sağlık hizmetlerinde; ileri teknolojiler kullanılarak erişilebilir çözümlerin üretilmesi, hasta ve çalışan memnuniyetinin artırılması, bakım kalitesinin iyileştirilmesi ve maliyetlerin düşürülmesi sağlanabilir. Bu derlemede evde sağlık hizmetlerinde teknoloji kullanımının önemini vurgulamayı ve bu hizmetlerde kullanılan teknolojilerden bazı örnekler vermeyi amaçladık.
- Published
- 2021
21. Clinical features of type 1 and type 2 diabetes patients with suspected fungal foot infections: a single-center experience
- Author
-
Selda Celik, Elif Bagdemir, Sevim Purisa, Ayse Kubat Uzum, Ilhan Satman, and Gulsah Yenidunya Yalin
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2022
22. Presenting Turkish Inappropriate Medication Use in the Elderly (TIME) Criteria Set in Turkish
- Author
-
Gülistan Bahat, Birkan İlhan, Tuğba Erdoğan, Meltem Halil, Sumru Savaş, Zekeriya Ülger, Filiz Akyüz, Ahmet Kaya Bilge, Sibel Çakır, Kutay Demirkan, Mustafa Erelel, Kerim Güler, Haşmet Hanağası, Belgin İzgi, Ateş Kadıoğlu, Ayşe Karan, Işın Baral Kulaksızoğlu, Ali Mert, Savaş Öztürk, İlhan Satman, Mehmet Şükrü Sever, Tufan Tükek, Yağız Üresin, Önay Yalçın, Nilüfer Yeşilot, Meryem Merve Ören, and Mehmet Akif Karan
- Published
- 2021
23. Monogenic Childhood Diabetes: Dissecting Clinical Heterogeneity by Next-Generation Sequencing in Maturity-Onset Diabetes of the Young
- Author
-
Hülya Yılmaz Aydoğan, Sukran Poyrazoglu, Ilhan Satman, Feyza Darendeliler, Kazim Yalcin Arga, Oğuz Öztürk, Gizem Gulfidan, Nurdan Gul, Deniz Kanca Demirci, Canan Cacina, Aslı Derya Kardelen Al, and Yildiz Tutuncu
- Subjects
0301 basic medicine ,Mutation, Missense ,Bioinformatics ,Biochemistry ,Maturity onset diabetes of the young ,ABCC8 ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Genetics ,medicine ,Humans ,Child ,Molecular Biology ,biology ,business.industry ,High-Throughput Nucleotide Sequencing ,Type 2 Diabetes Mellitus ,HNF1B ,medicine.disease ,Human genetics ,HNF1A ,030104 developmental biology ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Mutation ,biology.protein ,Molecular Medicine ,Personalized medicine ,business ,Biotechnology - Abstract
Diabetes is a common disorder with a heterogeneous clinical presentation and an enormous burden on health care worldwide. About 1-6% of patients with diabetes suffer from maturity-onset diabetes of the young (MODY), the most common form of monogenic diabetes with autosomal dominant inheritance. MODY is genetically and clinically heterogeneous and caused by genetic variations in pancreatic β-cell development and insulin secretion. We report here new findings from targeted next-generation sequencing (NGS) of 13 MODY-related genes. A sample of 22 unrelated pediatric patients with MODY and 13 unrelated healthy controls were recruited from a Turkish population. Targeted NGS was performed with Miseq 4000 (Illumina) to identify genetic variations in 13 MODY-related genes: HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, and KCNJ11. The NGS data were analyzed adhering to the Genome Analysis ToolKit (GATK) best practices pipeline, and variant filtering and annotation were performed. In the patient sample, we identified 43 MODY-specific genetic variations that were not present in the control group, including 11 missense mutations and 4 synonymous mutations. Importantly, and to the best of our knowledge, the missense mutations NEUROD1 p.D202E, KFL11 p.R461Q, BLK p.G248R, and KCNJ11 p.S385F were first associated with MODY in the present study. These findings contribute to the worldwide knowledge base on MODY and molecular correlates of clinical heterogeneity in monogenic childhood diabetes. Further comparative population genetics and functional genomics studies are called for, with an eye to discovery of novel diagnostics and personalized medicine in MODY. Because MODY is often misdiagnosed as type 1 or type 2 diabetes mellitus, advances in MODY diagnostics with NGS stand to benefit diabetes overall clinical care as well.
- Published
- 2021
24. Clinical outcomes of non-diabetic COVID-19 patients with different blood glucose levels: a nationwide Turkish study (TurCoGlycemia)
- Author
-
Selcuk Dagdelen, Tevfik Demir, Ilhan Satman, Ilker Tasci, Murat Caglayan, Rifat Emral, Ibrahim Sahin, Aysegul Atmaca, Cem Haymana, Osman Celik, Ugur Unluturk, Serpil Salman, Mustafa Sahin, Erman Cakal, Ibrahim Demirci, Alper Sonmez, Derun Taner Ertugrul, and Naim Ata
- Subjects
Adult ,Blood Glucose ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Mechanical ventilation ,COVID-19 Testing ,law ,Internal medicine ,Diabetes mellitus ,Medicine ,Humans ,Mortality ,Retrospective Studies ,ICU admission ,business.industry ,SARS-CoV-2 ,Mortality rate ,COVID-19 ,Retrospective cohort study ,medicine.disease ,Intensive care unit ,Icu admission ,Hospitalization ,030220 oncology & carcinogenesis ,Hyperglycemia ,Original Article ,Female ,business - Abstract
Purpose New coronavirus disease 2019 (COVID-19) has a worse prognosis in patients with diabetes. However, there are insufficient data about the effect of hyperglycemia on COVID-19 prognosis in non-diabetic patients. This study aimed to investigate the relationship between random blood glucose levels measured at the time of diagnosis and prognosis of COVID-19 disease in non-diabetic patients. Methods A nationwide retrospective cohort of non-diabetic patients with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. The patients were stratified into three groups according to blood glucose levels which were Results A total of 12,817 non-diabetic patients (median age [IQR]: 44 [25] years, females: 50.9%) were included. Patients in group-2 (5%) and group-3 (14%) had higher mortality rates than patients in group-1 (2.1%). The rates of hospitalization, hospital stays longer than 8 days, intensive care unit (ICU) admission, ICU stay more than 6 days, and mechanical ventilation were also significantly higher in group-3 patients. Likewise, glucose levels in the range of 140-199 mg/dL were an independent associate of mortality and composite of ICU admission and/or mechanical ventilation. ConclusionHyperglycemia at the time of COVID-19 diagnosis is associated with poor prognosis in non-diabetic patients. Clinicians should be more careful in the treatment of non-diabetic COVID-19 patients with hyperglycemia.
- Published
- 2021
25. Cytokine Profile in Patients With Maturity-onset Diabetes of the Young (MODY)
- Author
-
AYCA DIREN, DENIZ KANCA DEMIRCI, NURDAN GUL, BURCIN KARACANLI, AYKUT BAYKUT, YILDIZ TUTUNCU, OGUZ OZTURK, ILHAN SATMAN, HULYA YILMAZ-AYDOGAN, Tütüncü, Yıldız (ORCID 0000-0002-3905-6429 & YÖK ID 239430), Diren, A., Demirci, D.K., Gül, N., Karacanlı, B., Baykut, A., Öztürk, O., Satman, I., Yılmaz Aydoğan, H., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
- Subjects
Pharmacology ,Cancer Research ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Interleukin-17 ,Pro-inflammatory cytokines ,Hs-CRP ,HbA1c ,MODY ,MODY3 ,Diabetes ,Interleukin-23 ,Research and experimental medicine ,General Biochemistry, Genetics and Molecular Biology ,C-Reactive Protein ,Diabetes Mellitus, Type 2 ,Diabetes Mellitus ,Cytokines ,Humans ,Research Article - Abstract
Background/aim: high-sensitivity C-reactive protein (hs-CRP) is used in the differential diagnosis of maturity-onset diabetes of the young (MODY)-3, but other inflammatory markers have not been investigated in MODY patients. We aimed to compare the serum levels of anti-inflammatory and proinflammatory cytokines between MODY patients and healthy subjects and show the inflammatory features in MODY subtypes. Patients and methods: thirty patients with clinically suspected MODY and 34 healthy controls were included in this study. Next -generation sequencing (NGS) was used for the molecular diagnosis of MODY subtypes. Serum levels of cytokines were measured using a multiplexed cytokine assay and hs-CRP concentration was determined by the immunoturbidimetric assay. Results: the hs-CRP levels were higher in both NGS-confirmed (MODY, n=17) (p=0.009) and NGS-unconfirmed (non-MODY, n=13) patients (p, This study was supported by the Scientific Research Fund of Istanbul University within the scope of the project entitled “Investigation of Inflammatory Cytokine Profile in Maturity-Onset Diabetes of the Young (MODY)” (Project no. TSA-2017-25335). The Authors thank their patients and healthy control subjects who participated in the study
- Published
- 2022
26. Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing: Findings from the MODY-IST Study in Adult Patients
- Author
-
Hulya Yilmaz Aydogan, Nurdan Gul, Deniz Kanca Demirci, Ummu Mutlu, Gizem Gulfidan, Kazim Yalcin Arga, Aclan Ozder, Ahmet Adil Camli, Yildiz Tutuncu, Oguz Ozturk, Canan Cacina, Feyza Darendeliler, Sukran Poyrazoglu, Ilhan Satman, and ÖZDER, ACLAN
- Subjects
Diabetes Mellitus, Type 2 ,Mutation ,Genetics ,Mutation, Missense ,Molecular Medicine ,High-Throughput Nucleotide Sequencing ,Humans ,Findings from the MODY-IST Study in Adult Patients.-, Omics : a journal of integrative biology, 2022 [Aydogan H. Y. , Gul N., Demirci D. K. , Mutlu U., Gulfidan G., Arga K. Y. , Ozder A., Camli A. A. , Tutuncu Y., Ozturk O., et al., -Precision Diagnosis of Maturity-Onset Diabetes of the Young with Next-Generation Sequencing] ,Molecular Biology ,Biochemistry ,Biotechnology - Abstract
Maturity-onset diabetes of the young (MODY) is a highly heterogeneous group of monogenic and nonautoimmune diseases. Misdiagnosis of MODY is a widespread problem and about 5% of patients with type 2 diabetes mellitus and nearly 10% with type 1 diabetes mellitus may actually have MODY. Using next-generation DNA sequencing (NGS) to facilitate accurate diagnosis of MODY, this study investigated mutations in 13 MODY genes (
- Published
- 2022
27. Trends and Forecasts on Prediabetes and Diabetes in Adult and Elderly Population in Turkey
- Author
-
Ilhan Satman, Safak Bayirlioglu, Funda Okumus, Nazli Erturk, Merve Yemenici, Sedanur Cinemre, Gizem Gulfidan, Kazim Yalcin Arga, Yeliz Dogan Merih, and Halim Issever
- Abstract
Aims Diabetes is a chronic disease that limits the quality and duration of life. We aimed to estimate the trends in prediabetes and diabetes between 2010-2020, and the projections to 2023 and 2045 in Turkey. Materials and methods Prediabetes and diabetes estimates were calculated by direct standardization using age/sex-specific data from the previous TURDEP-II survey as reference. The 2010-2020 population demographics were obtained from TurkStat. Comparative age-adjusted diabetes rates were estimated using standard population models of world and Europe. ResultsEstimates depicted that the population (20-84 years) of any degree of glucose intolerance in Turkey increased by approximately 5.3 million (diabetes: 2.2 million and prediabetes: 3.1 million) from 2010 to 2020. While the increase in prediabetes and diabetes rates was 22% and 31.6% in overall population, corresponding increase were 45.2% and 45.6% in the elderly. Notably, diabetes awareness was comparable (54% and 58%). Age-specific prediabetes and diabetes rates were significantly higher in women than in men (diabetes: 14.1% versus 17%; prediabetes: 38.6% versus 30.2%). The comparative age-adjusted prevalence of diabetes to the standard European but not the world population model, showed a higher rate of 19.4%. According to the projections the prevalence of diabetes will reach 15.9% in 2023 and 19.1% in 2045. Conclusion Diabetes has reached epidemic proportions in Turkey and will continue to grow in the coming decades. The fact suggests that there is an urgent need to developing and implementing the country-specific prevention program to halt this increase. Otherwise, the burden of diabetes on social, economic and health services will continue to increase.
- Published
- 2022
28. Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START
- Author
-
Kutay Demirkan, Belgin Izgi, Ali Mert, Ates Kadioglu, Sibel Cakir, Mustafa Erelel, Onay Yalcin, Isin Baral Kulaksizoglu, Ahmet Kaya Bilge, Meryem Merve Oren, Savas Ozturk, Ilhan Satman, Hasmet Hanagasi, Gulistan Bahat, Mehmet Sukru Sever, Yağız Üresin, Nilufer Yesilot, Kerim Güler, Meltem Halil, Filiz Akyuz, Zekeriya Ulger, Ayşe Karan, Birkan Ilhan, Tugba Erdogan, Mehmet Akif Karan, Sumru Savas, Tufan Tükek, Kırıkkale Üniversitesi, KKÜ, and Ege Üniversitesi
- Subjects
medicine.medical_specialty ,Turkish ,TIME criteria ,Inappropriate Prescribing ,030209 endocrinology & metabolism ,Inappropriate medication use ,Drug Prescriptions ,03 medical and health sciences ,Elderly ,0302 clinical medicine ,Humans ,Medicine ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Set (psychology) ,Potentially Inappropriate Medication List ,Aged ,Geriatrics ,Polypharmacy ,Medication use ,business.industry ,language.human_language ,Eastern european ,Prescribing ,Family medicine ,Screening ,language ,Stop time ,business ,Inclusion (education) ,Research Paper - Abstract
Key summary points Aim To meet the current need in different European countries for improving prescribing in older adults, we aimed to create an update screening tool getting origin from the two user friendly criterion sets: the STOPP/STARTv2 criteria and CRIME criteria. Findings Based on thorough literature review, 55 criteria were added, 17 criteria were removed, and 60 criteria were modified. As a result, 153 TIME criteria composed of 112 TIME-to-STOP and 41 TIME-to-START criteria were introduced. Message TIME criterion set is an update screening tool reported from Eastern Europe that included experts from geriatrics and other specialties frequently giving care to older adults and some additional practical explanations for clinical use. Electronic supplementary material The online version of this article (10.1007/s41999-020-00297-z) contains supplementary material, which is available to authorized users., Purpose To improve prescribing in older adults, criterion sets have been introduced from different countries. While current criterion sets are useful to some extent, they do not meet the need in some European countries. Turkish inappropriate medication use in the elderly (TIME) criteria was planned to meet this need. Methods In phase 1, the user friendly sets: STOPP/START version2 and CRIME criteria were combined. National experts composed of geriatricians and non-geriatricians were invited to review and comment. In phase 2, thorough literature review was performed and reference-based revisions, omissions, and additions were made. Explanatory additions were added to some criteria to improve application in practice. In phase 3, all working group members reviewed the criteria/explanations and agreed on the final content. Results Phase 1 was performed by 49 expert academicians between May and October 2016. Phase 2 was performed by 23 working group academicians between October 2016 and November 2018 and included face-to-face interviews between at least two geriatrician members and one criterion-related specialist. Phase 3 was completed between November 2018–March 2019 with review and approval of all criteria by working group academicians. As a result, 55 criteria were added, 17 criteria were removed, and 60 criteria were modified from the first draft. A total of 153 TIME criteria composed of 112 TIME-to-STOP and 41 TIME-to-START criteria were introduced. Conclusion TIME criteria is an update screening tool that differs from the current useful tools by the interactive study of experts from geriatrics and non-geriatrics, inclusion of practical explanations for some criteria and by its eastern European origin. TIME study respectfully acknowledges its roots from STOPP/START and CRIME criteria. Studies are needed whether it would lead improvements in older adults’ health. Electronic supplementary material The online version of this article (10.1007/s41999-020-00297-z) contains supplementary material, which is available to authorized users.
- Published
- 2020
29. Turkish Adaptation of Michigan Diabetes Research and Training Center’s Revised Diabetes Knowledge Test and Determination of Factors Affecting the Knowledge Level of Diabetic Individuals
- Author
-
Melike Dişsiz, Selda Celik, Ilhan Satman, Elif Bağdemir, and Cemile Idiz
- Subjects
Gerontology ,business.industry ,Turkish ,Endocrinology, Diabetes and Metabolism ,Knowledge level ,medicine.disease ,language.human_language ,Training center ,Diabetes mellitus ,Internal Medicine ,language ,Medicine ,Knowledge test ,business ,Adaptation (computer science) - Published
- 2020
30. EVALUATION OF SARCOPENIA, MALNUTRITION AND NUTRITIONAL STATUS OF PATIENTS WITH AND WITHOUT CANCER TREATMENT BY AGE
- Author
-
Tuğçe Aytulu, Fatih Selçukbiricik, Bedia Çalıkoğlu, Meltem Yılmaz, Gözde Ergene, Halim İşsever, and İlhan Satman
- Subjects
Kanser,sarkopeni,geriatri,beslenme,malnütrisyon ,Cancer,sarcopenia,geriatric,nutrition,malnutrition ,Medicine ,Tıp - Abstract
Amaç: Kemoterapiye yeni başlayacak veya başlamış olan, geriatrik olan ve olmayan hastalarda sarkopeninin ve beslenme durumunun değerlendirilmesidir. Gereç ve Yöntem: Bu çalışmada, ilk kez kemoterapi alacak yetişkin kanser hastalar, kemoterapi tedavisinin 3.ayı ile 1.yılı arasında olan hastalarla sarkopeni yönünden ve beslenme durumları açısından değerlendirilmiştir. Hastaların geriatrik olup olmamasına göre karşılaştırılmış ve ayrıca sarkopenik olan hastalar kanser türlerine göre sınıflandırılarak da değerlendirilmiştir. Hastaların el kavrama kuvvetleri, biyoelektrik impedans ile apendiküler iskelet kas indeksi (boya göre düzeltilmiş), yürüme hızları ölçülmüş ve sarkopenik düzeyleri, malnütrisyon riskleri, üç günlük besin tüketim kayıtları ve laboratuvar parametreleri incelenmiştir. Bulgular: Toplamda 123 yetişkin hasta değerlendirilmiştir. Çalışmadaki hastaların 58’i (%47,2’si) geriatriktir (65 yaş ≥) ve %39’unun malnütrisyon riski yüksektir. Geriatrik olan grupta (%46,6) olmayanlara göre (%32,3) anlamlı derecede malnütrisyon riski yüksek bulunmuştur (p=0,029). Malnütrisyon riski kanserin tanı gruplarıyla da ilişkili bulunmuştur. Meme kanserine göre, malnütrisyon riskinin hepatobiliyer kanserlerde (pankreas dahil) 18,2 kat (p=0,002) ve diğer kanserlerde (baş-boyun, sarkom, beyin, mide, periton) 7,6 kat (p=0,018) daha yüksek olduğu görülmüştür. Sonuç: Özellikle geriatrik hastalarda, kanserin neden olduğu malnütrisyonun, tedavinin başlangıcında farkedilmesi ve değerledirilmesi önemlidir., Objective: The aim of this study is to evaluate patients who are just starting or have started chemotherapy and also who are geriatric and nongeriatric, of sarcopenia and nutritional status. Materials and Methods: In this study, adult cancer patients who will receive chemotherapy for the first time were evaluated in terms of sarcopenia and nutritional status with patients between the 3rd month and 1st year of chemotherapy treatment. Patients were compared according to whether they were geriatric or not, and sarcopenic patients were also evaluated by classifying them according to cancer sides. The patients’ hand grip strength, bioelectrical impedance, appendicular skeletal muscle index (corrected for height), walking speed were measured and evaluated for sarcopenia. In addition, malnutrition risks, three-day food consumption records and laboratory parameters were examined. Results: A total of 123 adult patients were evaluated and 58 (47.2%) of the patients in the study were geriatric (65 years ≥). The risk of malnutrition was high in 39% of the patients and was found to be significantly higher in the geriatric group (46.6%) than in the non-geriatric group (32.3%) (p=0.029). The risk of malnutrition was found to be associated with the diagnosis groups of cancer. Compared to breast cancer, the risk of malnutrition was 18.2 times (p=0.002) higher in hepatobiliary cancers (including pancreas) and 7.6 times (p=0.018) in other cancers (head and neck, sarcoma, brain, stomach, peritoneum). Conclusion: Especially in geriatric patients, it is important to recognize and evaluate malnutrition caused by cancer at the beginning of treatment.
- Published
- 2021
31. The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study
- Author
-
Selcuk Dagdelen, Ugur Unluturk, Emral Rıfat, Ilker Tasci, Tevfik Demir, Serpil Salman, Alper Sonmez, Ibrahim Sahin, Aysegul Atmaca, Osman Celik, Erman Cakal, Mustafa Sahin, Cem Haymana, Ibrahim Demirci, Ilhan Satman, Murat Caglayan, Naim Ata, and Derun Taner Ertugrul
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Disease ,law.invention ,Iodine Radioisotopes ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Interquartile range ,law ,COVID‐19 ,Internal medicine ,medicine ,thyroid cancer ,Humans ,Thyroid Neoplasms ,Thyroid cancer ,Retrospective Studies ,business.industry ,SARS-CoV-2 ,Mortality rate ,COVID-19 ,Retrospective cohort study ,Original Articles ,medicine.disease ,Intensive care unit ,mortality ,radioactive iodine therapy ,Standardized mortality ratio ,030220 oncology & carcinogenesis ,Original Article ,business ,Kidney disease - Abstract
Background There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID‐19) disease outcomes and mortality. Here, we evaluated COVID‐19 infection outcomes and mortality in thyroid cancer patients with COVID‐19 infection. Design and methods We included a cohort of patients with thyroid cancer with PCR‐confirmed COVID‐19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID‐19 disease. Results We evaluated 388 COVID‐19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender‐matched 388 COVID‐19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non‐cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID‐19 disease in our patient group. Conclusions Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID‐19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.
- Published
- 2021
32. Higher rate of covid-19 mortality in patients with type 1 than type 2 diabetes: a nationwide study
- Author
-
Ibrahim Sahin, Ilhan Satman, Erman Cakal, Osman Celik, Aysegul Atmaca, Ibrahim Demirci, Serpil Salman, Mustafa Sahin, Alper Sonmez, Ilker Tasci, Naim Ata, Selcuk Dagdelen, Ugur Unluturk, Murat Caglayan, Rifat Emral, Cem Haymana, Derun Taner Ertugrul, Tevfik Demir, and Suayip Birinci
- Subjects
medicine.medical_specialty ,endocrine system diseases ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Endocrinology, Diabetes and Metabolism ,COVID-19 ,nutritional and metabolic diseases ,Type 2 diabetes ,medicine.disease ,Hospitalization ,Endocrinology ,Diabetes Mellitus, Type 1 ,Diabetes Mellitus, Type 2 ,Internal medicine ,medicine ,Humans ,In patient ,business ,Retrospective Studies - Abstract
PurposeCOVID-19 disease has a worse prognosis in patients with diabetes, but the comparative data about the course of COVID-19 in patients with type 1 (T1DM) and type 2 diabetes (T2DM) are lacking. The purpose of this study was to find out the relative clinical severity and mortality of COVID-19 patients with T1DM and T2DM.MethodsA nationwide retrospective cohort of patients with confirmed (PCR positive) COVID-19 infection (n=149,671) was investigated. After exclusion of individuals with unspecified diabetes status, the adverse outcomes between patients with T1DM (n=163), T2DM (n=33,478) and the non-diabetics (n=115,108) were compared by using the propensity score matching method. The outcomes were hospitalization, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality.ResultsThe patients with T1DM had higher mortality than the age and gender matched patients with T2DM (n=489) and the non-diabetics (n=489) (pConclusionAccording to the results, patients with T1DM had poorer COVID-19 prognosis than those with T2DM or the non-diabetics. These patients should be cared diligently until more data will be available about the causes of increased COVID-19 mortality in T1DM.
- Published
- 2021
33. Üniversite Öğrencilerinde Tütün Kullanım Alışkanlıklarının Belirleyicileri Ve Algılar: İstanbul İlinde Sağlık Meslek Yüksekokulu Öğrencileri Örneği
- Author
-
Nazlı Ertürk, Kazım Yalçın Arğa, Selda Selimoglu Namoglu, Özden Güdük, Merve Yemenici, Yeliz Doğan Merih, and Ilhan Satman
- Subjects
Davranış ,Behavior ,Cigarettes ,Nargile ,Tobacco ,Tütün ,Sigara ,Üniversite Öğrencisi ,Tobacco Products ,Waterpipe (Narghile) ,University Student ,Tütün Ürünleri - Abstract
Amaç: Sağlık Meslek Yüksekokulu öğrencilerinin tütün ve tütün ürünleri kullanma davranışlarını incelemek ve bu davranış üzerinde belirleyicifaktörleri ortaya koymaktır.Yöntem: Bu araştırma, Medipol Üniversitesi Sağlık Hizmetleri Meslek Yüksekokulu’nda gerçekleştirilmiştir. Toplam 26 soruluk olarakhazırlanan, yapılandırılmış bir anket, 307 öğrenciye yüz yüze uygulanmıştır. Veriler, SPSS 23 programı kullanılarak Pearson ki-karekorelasyon testi ve binary lojistik regresyon modeli ile analiz edilmiştir. Çalışma öncesi İstanbul Medipol Üniversitesi Girişimsel OlmayanAraştırmalar Etik Kurulu’ndan onay alınmıştır.Bulgular: Anket verileri öğrencilerin %32.6’sının tütün ürünleri (sıklıkla sigara) kullandığını, erkek öğrencilerin sigara kullanma alışkanlığısıklığının daha yüksek olduğunu, daha erken yaşlarda sigara kullanmaya başladıklarını ve günlük tüketim miktarının (adedinin) daha fazlaolduğunu göstermiştir. Sigara kullanma davranışının gelişmesinde “sigara sağlığa zararlıdır” düşüncesine sahip olmanın azaltıcı, bunakarşılık sık görüşülen arkadaşların sigara kullanmasının artırıcı etkisi olduğu görülmüştür. Üniversite eğitiminin ilk ve son yıllarıkarşılaştırıldığında, sigara kullanan öğrenci sayısının zamanla arttığı saptanmıştır.Sonuç: Önceki yıllara göre, toplumumuzda Sağlık Meslek Yüksekokulu öğrencileri arasında sigara ve nargile kullanımı artmaktadır. Bu artıştacinsiyet, arkadaş etkisi, merak, özenti, stres ve kültürel özellikler ön plana çıkmaktadır. Bu nedenle tütün ürünleri ile mücadele politikalarındabu hususların dikkate alınması önem arz etmektedir. Aim: To examine tobacco and tobacco use behaviors of the students of Health Vocational School and to reveal the determining factors on this behavior. Methods: This research was carried out in Medipol University Health Services Vocational School. A structured questionnaire with a total of 26 questions was applied to 307 students face to face. The data were analyzed using the SPSS 23 program by Pearson chi-square test and binary logistic regression model. Before the study, approval was obtained from the Medipol University Non-Invasive Research Ethics Committee. Results: The survey data showed that 32.6% of the students used tobacco products (mainly cigarettes), the frequency of smoking habit of male students was higher, they started smoking at an earlier age and the amount of daily consumption was higher. In the development of smoking behavior, it has been observed that having the belief of “smoking is harmful for health” has a decreasing effect, whereas smoking of frequently seen friends has an increasing effect. When the first and last years of university education are compared, it is found that the number of students who smoke increases over time. Conclusion: Compared to previous studies, smoking and waterpipe use are increased among Health Vocational School students in our society. In this increase, gender, peer influence, curiosity, interest, stress, and cultural characteristics come to the front. For this reason, it is important to consider these issues in policies to combat tobacco products.
- Published
- 2021
34. Clinical characteristics and outcomes of COVID‐19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia)
- Author
-
Osman Celik, Murat Caglayan, Naim Ata, Ibrahim Demirci, Ilhan Satman, Ibrahim Sahin, Ilker Tasci, Rifat Emral, Derun Taner Ertugrul, Selcuk Dagdelen, Aysegul Atmaca, Tevfik Demir, Cem Haymana, Alper Sonmez, Ugur Unluturk, Erman Cakal, Serpil Salman, and Mustafa Sahin
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Turkey ,Endocrinology, Diabetes and Metabolism ,intensive care unit admission ,030209 endocrinology & metabolism ,Type 2 diabetes ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,law ,COVID‐19 ,Internal medicine ,Diabetes mellitus ,Outcome Assessment, Health Care ,Medicine ,Humans ,Epidemics ,Aged ,Retrospective Studies ,Glycated Hemoglobin ,business.industry ,SARS-CoV-2 ,Hazard ratio ,Type 2 Diabetes Mellitus ,COVID-19 ,Retrospective cohort study ,Original Articles ,Length of Stay ,Middle Aged ,medicine.disease ,Intensive care unit ,mortality ,Respiration, Artificial ,hospital stay ,Hospitalization ,Intensive Care Units ,Diabetes Mellitus, Type 2 ,Propensity score matching ,Original Article ,Female ,type 2 diabetes ,business - Abstract
Background Coronavirus disease 2019 (COVID‐19) has been reported to be associated with a more severe course in patients with type 2 diabetes mellitus (T2DM). However, severe adverse outcomes are not recorded in all patients. In this study, we assessed disease outcomes in patients with and without T2DM hospitalized for COVID‐19. Methods A nationwide retrospective cohort of patients with T2DM hospitalized with confirmed COVID‐19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. Multivariate modeling was used to assess the independent predictors of demographic and clinical characteristics with mortality, length of hospital stay, and intensive care unit (ICU) admission and/or mechanical ventilation. Results A total of 18 426 inpatients (median age [interquartile range, IQR]: 61 [17] years; males: 43.3%) were investigated. Patients with T2DM (n = 9213) were compared with a group without diabetes (n = 9213) that were matched using the propensity scores for age and gender. Compared with the group without T2DM, 30‐day mortality following hospitalization was higher in patients with T2DM (13.6% vs 8.7%; hazard ratio 1.75; 95% CI, 1.58‐1.93; P, Highlights Coronavirus disease 2019 (COVID‐19) takes an unfavorable course in patients with type 2 diabetes mellitus (T2DM), and the risk increases in individuals with certain conditions, some of which are not modifiable.This study showed significantly higher mortality due to COVID‐19 in hospitalized patients with T2DM than without (13.6% vs 8.7%; hazard ratio 1.75; 95% CI, 1.58‐1.93).Older age, male gender, obesity, preexisting insulin treatment, low lymphocyte count, and pulmonary involvement on admission were the significant associates of COVID‐19 mortality.
- Published
- 2021
35. Gençlerin Erişkin Başlangıçlı Diyabeti (MODY) Sorumlu HNF4A, GCK ve HNF1 Gen Varyasyonlarının Dünya Genelinde Coğrafik Dağılımı
- Author
-
Oğuz Öztürk, Ilhan Satman, Hülya Yilmaz Aydoğan, Nurdan Gul, and Deniz Kanca Demirci
- Subjects
business.industry ,Basic Sciences ,Temel Bilimler ,Medicine ,MODY,HNF1A,HNF4A,GCK ,General Medicine ,business ,Molecular biology - Abstract
Gençlerin Erişkin Başlangıçlı Diyabeti (MODY) otozomal dominant kalıtım ile karakterize monogenik bir hastalıktır. Şimdiye kadar 14 farklı gende çok sayıda heterozigot mutasyonlar tanımlanmış olup bu mutasyonların dağılımı her ülkede farklıdır. Çalışmamızda yaygın MODY alt tipleri, MODY1-3, için literatür araştırması yaparak HNF4A, GCK ve HNF1A genlerindeki yanlış anlamlı mutasyonları özetledik. Ancak Asya populasyonlarında bilinen MODY genleri bu diyabetik bireylere tanı koymak için yeterli olmayıp çoğu MODYX olarak tanımlanmaktadır. Dahası, Avrupa ülkeleri ile kıyaslandığında Çin, Japonya, Kore ve Hindistan populasyonlarında MODY prevalansında çelişkiler mevcut olup hastalığın genetik alt yapısının daha iyi anlaşılması için daha fazla genetik çalışmaya ihtiyaç duyulmaktadır.
- Published
- 2021
36. Correction to: Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
- Author
-
Rifat Emral, Cem Haymana, Ibrahim Demirci, Ilker Tasci, Mustafa Sahin, Erman Cakal, Naim Ata, Ugur Unluturk, Tevfik Demir, Derun Ertugrul, Ibrahim Sahin, Aysegül Atmaca, Osman Celik, Murat Caglayan, Kazim Yalcin Arga, Selcuk Dagdelen, Serpil Salman, Ilhan Satman, and Alper Sonmez
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2021
37. TİP 2 DİYABETLİ YAŞLI BİREYLERDE KIRILGANLIĞI ETKİLEYEN FAKTÖRLER NELERDİR?
- Author
-
Mehmet Akif Karan, Ramazan Çakmak, Ozlem Yilmaz, Gulistan Bahat, Sakin Tekin, Sena Gürkaş, Ilhan Satman, Meryem Merve Oren, Nurdan Gul, and Cemile Idiz
- Subjects
Gynecology ,medicine.medical_specialty ,Health Care Sciences and Services ,business.industry ,medicine ,Elderly people ,Kırılganlık,yaşlılık,diyabet,malnütrisyon,depresyon,yaşam kalitesi ,Type 2 diabetes ,Sağlık Bilimleri ve Hizmetleri ,medicine.disease ,business ,Frailty,elderly,diabetes,malnutrition,depression,quality of life - Abstract
Amaç: Çalışmamızın amacı tip 2 diyabet tanısı almış yaşlı erişkinlerde kırılganlıkla ilgili faktörleri belirlemektir. Gereç ve Yöntem: Çalışmaya 65 yaş ve üstü, tip 2 diyabet tanısı almış 108 kişi dahil edildi. Katılımcıların kırılganlığı FRAIL anketi ile değerlendirilmiş, beslenme durumu Mini Beslenme Değerlendirme Kısa Formu (MNA-SF) ile, depresyon durumu Hasta Sağlığı Anketi-2 (PHQ2) ve Geriatrik Depresyon Ölçeği Kısa Formu (GDS-SF) ile değerlendirilirken, yaşam kalitesi EuroQol-5 Boyut (EQ5D) ve EQ VAS puanlaması ile, kişisel bakım durumları ise Günlük Yaşamın Temel Aktiviteleri (BADL) ve Günlük Yaşamın Enstrümantal Aktiviteleri (IADL) formları ile değerlendirilmiştir. Bulgular: Kırılgan grupta, kırılgan olmayanlara göre uyku sorunları, düşme korkusu, idrar kaçırma, PHQ2, GDS-SF ve EQ5D skorları anlamlı olarak yüksek; MNASF skoru ise anlamlı olarak düşüktü (p, Objective: Our study aimed to determine the factors related to frailty in elderly adults having been diagnosed with type 2 diabetes mellitus. Material and Method: A total of 108 people aged 65 and over, diagnosed with type 2 diabetes, were included in the study. The frailty of the participants was evaluated with the FRAIL questionnaire, their nutritional status was evaluated with the Mini Nutrition Assessment Short Form (MNA-SF), the depression status with the Patient Health Questionnaire-2 (PHQ2) and the Geriatric Depression Scale Short Form (GDS-SF), while the quality of life was evaluated with the EuroQol-5 Dimension (EQ5D) and Scoring the EQ-VAS, and personal care status were evaluated with Basic Activities of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL) forms. Results: Sleep problems, fear of falling, presence of urinary incontinence, PHQ2, GDS-SF, and EQ5D scores were significantly higher; the MNASF score was significantly lower in the frail group than the values in the non-frail group (p
- Published
- 2021
38. 1378-P: Are Nutritional Habits Equally Associated with the Risk of Gestational Diabetes and Gestational Glucose Intolerance?
- Author
-
Ilhan Satman, Merve Yabaci, Atil Yuksel, Cemile Idiz, Birsen Demirel, Emel Özer, Fulya Turker, and Beyhan Omer
- Subjects
Normal glucose tolerance ,Pregnancy ,medicine.medical_specialty ,business.industry ,Obstetrics ,Endocrinology, Diabetes and Metabolism ,medicine.disease ,Logistic regression ,Gestational diabetes ,Human nutrition ,Diabetes mellitus ,Internal Medicine ,medicine ,Gestation ,Family history ,business - Abstract
Objective: The aim of this study is to investigate the relationships between the nutritional characteristics of pregnant women and the risk of gestational diabetes mellitus (GDM) and Gestational Glucose Intolerance (GGIT). Materials and Method: Women were investigated for GDM during the 24th to 28th weeks of pregnancy. According to the two-step diagnostic approach, women with normal glucose tolerance (normal), those with only 1 high glucose (GGIT) and those with at least 2 high values (GDM) in OGTT were included in the study. There was 60 pregnant women in each group (mean age 31.6±5.4; range 19-46 years). Demographic and clinical characteristics of the participants were questioned and a 3-day food consumptions record were evaluated with BEBIS program. Results: The mean weight, BMI and daily fiber intake in GDM group were significantly higher than the normal group. In the GDM and GGIT groups, the mean age, weight, daily carbohydrate (CHO) and protein intakes, and family history of diabetes were higher than those with normal group. Moreover, in the GDM group, daily fat intake was also significantly higher than the normal and GGIT groups. According to the separate models of logistic regression analysis; the age; daily protein, CHO and fat consumptions; having the first pregnancy and higher pre-pregnancy BMI (>25 kg/m2) were associated with increased likelihood of GDM. Similarly, the age, daily protein consumption, history of giving birth to a macrosomic baby and current smoking were positively linked with the risk of GGIT. Conclusion: Women’s nutritional habits (excessive CHO, fat and especially protein consumptions), phenotypic characteristics, family history of diabetes and poor obstetric history are similarly related to the risk of developing GDM and GGIT. Our results showed that in all women, particularly in those at high-risk for GDM who are planning pregnancy, a special attention should be given to general health and balanced diet, starting from pre-pregnancy. Disclosure M. Yabaci: None. I. Satman: None. C. Idiz: None. F. Turker: None. A. Yuksel: None. B. Omer: None. B. Demirel: None. E. Ozer: None. Funding Istanbul University
- Published
- 2020
39. Determination of genetic changes of Rev-erb beta and Rev-erb alpha genes in Type 2 diabetes mellitus by next-generation sequencing
- Author
-
Nurdan Gul, Bengu Tokat, Deniz Kanca-Demirci, Ozlem Kucukhuseyin, Hulya Yilmaz-Aydogan, Oğuz Öztürk, Ilhan Satman, Aclan Ozder, and ÖZDER, ACLAN
- Subjects
0301 basic medicine ,Silent mutation ,Male ,medicine.medical_specialty ,viruses ,Alpha (ethology) ,Receptors, Cytoplasmic and Nuclear ,Single-nucleotide polymorphism ,Biology ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,0302 clinical medicine ,Genetic ,Internal medicine ,Genotype ,Genetics ,medicine ,Missense mutation ,Humans ,Allele ,Beta (finance) ,skin and connective tissue diseases ,General Medicine ,Middle Aged ,medicine.disease ,body regions ,Repressor Proteins ,030104 developmental biology ,Endocrinology ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,Nuclear Receptor Subfamily 1, Group D, Member 1 ,Microalbuminuria ,Female - Abstract
Background: The nuclear receptors Rev-erb alpha and Rev-erb beta are transcription factors that regulate the function of genes in glucose and lipid metabolism, and they also form a link between circadian rhythm and metabolism. We evaluated the variations in Rev-erb alpha and Rev-erb beta genes together with biochemical parameters as risk factors in type 2 diabetic (T2DM) patients. Methods: Molecular analyses of Rev-erb alpha and Rev-erb beta genes were performed on genomic DNA by using next-generation sequencing in 42 T2DM patients (21 obese and 21 non-obese) and 66 healthy controls. Results: We found 26 rare mutations in the study groups, including 13 missense mutations, 9 silent mutations, 3 5'UTR variations, and a 3'UTR variation, of which 9 were novel variations (5 missense and 3 silent and 1 5'UTR). Six common variations were also found in the Rev-erb genes; Rev-erb beta Chr3:24003765 A > G, Rev-erb beta rs924403442 (Chr3:24006717) G > T, Rev-erb alpha Chr17:38253751 T > C, Rev-erb alpha rs72836608 C > A, Rev-erb alpha rs2314339 C > T and Rev-erb alpha rs2102928 C > T. Of these, Rev-erb beta Chr3:24003765 A > G was a novel missense mutation (p.Q197R), while others were identified as intronic variants. T2DM patients with Rev-erb beta rs924403442 T allele had lower body surface area (BSA) than noncarriers (GG genotype) (p = 0.039). Rev-erb alpha rs72836608 A allele and Rev-erb alpha rs2314339 CC genotype were associated with decreased serum HDL-cholesterol levels in T2DM patients (p = 0.025 and p = 0.027, respectively). In our study, different effects of Rev-erbs polymorphisms were found according to gender and presence of obesity. Rev-erb alpha rs72836608 (C > A) and rs2314339 (C > T) and Rev-erb alpha rs2102928 (C > T) were associated with low HDL-C levels in male T2DM patients. In female patients, Rev-erb alpha rs2102928 (C > T) was associated with high microalbuminuria and Rev-erb beta rs9244403442 G > T was associated with low HDL and high BSA values. In addition, Rev-erb alpha Chr17: 38,253,751 (T > C), rs72836608 (C > A), and rs2314339 (C > T) and Rev-erb beta Chr3:24003765 (A > G) were associated with increased serum GGT levels in obese T2DM patients. In non-obese patients, Rev-erbs SNPs had no effect on serum GGT levels. Conclusion: Our findings indicate that variations in the Rev-erb alpha and Rev-erb beta genes can affect metabolic changes in T2DM and these effects may vary depending on gender and obesity. İstanbul Üniversitesi
- Published
- 2020
40. Additional file 1 of Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
- Author
-
Bayram, Fahri, Sonmez, Alper, Haymana, Cem, Sabuncu, Tevfik, Oguzhan Sitki Dizdar, Gurkan, Eren, Ayse Kargili Carlioglu, Agbaht, Kemal, Ozdemir, Didem, Demirci, Ibrahim, Barcin, Cem, Salman, Serpil, Tetiker, Tamer, Balci, Mustafa Kemal, Kebapci, Nur, Ersoy, Canan, Yumuk, Volkan, Toth, Peter P., and Ilhan Satman
- Subjects
Data_FILES - Abstract
Additional file 1.
- Published
- 2020
- Full Text
- View/download PDF
41. Diyabetlilerde Kendi Kendine Kan Şekeri İzlemi ile HbA1c ve Diyabet Komplikasyonlarının Karşılaştırılması
- Author
-
Ilhan Satman, Elif Bagdemir, Sevim Purisa, Nevin Dinccag, Selda Celik, and Cemile Idiz
- Subjects
medicine.medical_specialty ,Type 1 diabetes ,business.industry ,Type 2 diabetes ,medicine.disease ,Gastroenterology ,Diabetic foot ,Nephropathy ,Internal medicine ,Diabetes mellitus ,Medicine ,Hemoglobin ,Blood Glucose Measurement ,business ,Retinopathy - Abstract
Aim: This study aimed to determine the relationship between the frequency of measuring blood glucose levels and the complications and regulation of diabetes in patients under follow-up due to diabetes mellitus. Subjects and Method: This study was conducted via retrospective evaluation of patient files of 951 diabetics (90 with type 1 diabetes and 861 with type 2 diabetes). Patient information including age, gender, height, weight, type of diabetes, duration of diabetes, treatment of diabetes, hemoglobin A1c (HbA1c) value, presence of neuropathy, presence of nephropathy, presence of diabetic foot, presence of hypertension, and frequency of measuring blood glucose levels were recorded. Patients were divided into 3 groups by the frequency of measuring blood glucose levels, where those who measured blood glucose levels a total of 8 times for at least two days a week were assigned to group 1, those who measured blood glucose levels less than 8 times for less than two days a week were assigned to group 2, and those who measured blood glucose levels 8 times in the 2 days prior to the control visit, who had previously measured blood glucose levels in an irregular manner were assigned to group 3. Results: Of the patients, 548 were females and 403 were males, with a mean age of 58.12±13.17 years. There was a significant difference in the parameters of HbA1c (p
- Published
- 2018
42. The Endocrine Society’s 100th Annual Meeting and Expo
- Author
-
Oğuz Öztürk, Ayca Diren, Aykut Baykut, Yildiz Tutuncu, Ilhan Satman, Nurdan Gul, Hülya Yılmaz Aydoğan, Burçin Karacanli, and Deniz Kanca Demirci
- Subjects
Endocrinology ,Cytokine ,business.industry ,Endocrinology, Diabetes and Metabolism ,Potential biomarkers ,medicine.medical_treatment ,Immunology ,Medicine ,Differential diagnosis ,business - Published
- 2018
43. Awareness of Diabetes and Obesity in Turkey
- Author
-
Ilhan Satman, Nevin Dinççağ, Selda Celik, Sevda Ozel Yildiz, Cemile Idiz, and Yildiz Tutuncu
- Subjects
Gerontology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Diabetes mellitus ,Internal Medicine ,medicine ,medicine.disease ,business ,Obesity - Published
- 2017
44. Physical Activity Indicators, Metabolic Biomarkers, and Comorbidity in Type 2 Diabetes
- Author
-
Seldan Çelik, Buket Akinci, İpek Yeldan, Ilhan Satman, and Sağlık Bilimleri Fakültesi
- Subjects
Oncology ,Insulin Therapy ,Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Physical activity ,030209 endocrinology & metabolism ,Physical Therapy, Sports Therapy and Rehabilitation ,Predictor variables ,Type 2 diabetes ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Metabolic Biomarkers ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Orthopedics and Sports Medicine ,Exercise ,Glycated Hemoglobin ,Metabolic biomarkers ,030229 sport sciences ,General Medicine ,Physical Activity ,Middle Aged ,medicine.disease ,Comorbidity ,Lipids ,Physical activity level ,Type 2 Diabetes ,Diabetes Mellitus, Type 2 ,Nephrology ,Female ,Sedentary Behavior ,Biomarkers - Abstract
Purpose: This study aimed (1) to compare physical activity (PA) indicators, metabolic biomarkers, and comorbidity, (2) to investigate the relationship between PA indicators and metabolic biomarkers, comorbidity and (3) to identify barriers to PA in patients with type 2 diabetes (T2DM) who are using oral hypoglycaemic agent (OHA) or combined OHA and insulin (OHAiN). Methods: Sixty-one patients were classified as patients using only OHA or combined OHAiN. Metabolic biomarkers (waist-to-hip ratio, body mass index (BMI), lipid profile, glycosylated haemoglobin (HbA1c), fasting blood glucose, comorbidity and PA indicators (self-reported PA, number of steps (NOS), 6-minute walking distance (6MWD)) were assessed. PA perceptions and reasons for inactivity were questioned. Results: The comorbidity (p = .013), low-density lipoprotein-cholesterol (p = .026), total cholesterol (p = .008) and HbA1c (p = .020) were higher and PA level was lower (p = .007) in the OHAiN group. NOS was positively correlated with high-density lipoprotein-cholesterol (p = .037) and negatively correlated with BMI (p = .007). 6MWD was negatively correlated with BMI (p = .014) and comorbidity (p = .004) in the OHA group. BMI was a significant predictor of NOS (adjusted R2 = 0.242) and comorbidity for 6MWD (adjusted R2 = 0.250) in the OHA group. The majority of the patients (OHA = 34.3%, OHAiN = 42.3%) reported "lack of time" as the most common barrier to PA. Conclusions: This study showed that patients on OHAiN have lower PA levels, poorer metabolic profiles, and higher comorbidity rates than OHA users. PA indicators were related with some metabolic biomarkers and comorbidity in only OHA users. The most common reason for inactivity was "the lack of time" in both groups.
- Published
- 2019
45. Fine-scale haplotype mapping of MUT, AACS, SLC6A15 and PRKCA genes indicates association with insulin resistance of metabolic syndrome and relationship with branched chain amino acid metabolism or regulation
- Author
-
Stéphanie Badiou, Christophe Normand, Yves Rinato, Timo Kanninen, Abdelhamid Barakat, Jean Frederic Brun, Florin Grigorescu, Jean-Marie Robine, Serghey Litvinov, Michel Pugeat, Ramon Gomis, Josep Maria Macias, Nicoleta Baculescu, Catalina Poiana, Carmen Emanuela Georgescu, Sara Haydar, Corin Badiu, Elza Khusnutdinova, Thibault Sutra, Yannick Cogne, Jacques Mercier, Renato Pasquali, Corinne Lautier, Saša Missoni, Dorina Ylli, Agron Ylli, Akila Zenati, Davide Lauro, Jean-Paul Cristol, Eric Renard, Agathocles Tsatsoulis, Monica Livia Gheorghiu, Giorgio Sesti, Sonia Abdelhak, Vincenzo Trischitta, Madalina Vintila, Yildiz Tutuncu, Ilhan Satman, Patrick Poucheret, Sabrina Prudente, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Mécanismes moléculaires dans les démences neurodégénératives (MMDN), Université Montpellier 2 - Sciences et Techniques (UM2)-École pratique des hautes études (EPHE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Recherche pour le Développement (IRD), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de biologie moléculaire eucaryote (LBME), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Démarche intégrée pour l'obtention d'aliments de qualité (UMR Qualisud), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Université de La Réunion (UR)-Université de Montpellier (UM)-Avignon Université (AU)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Montpellier 1 (UM1), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Département de biochimie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Diabetes and Obesity Laboratory, Endocrinology and Nutrition Unit-Hospital Clinic, Institute of Biochemistry and Genetics of Ufa Scientific Centre, Russian Academy of Sciences [Moscow] (RAS), Division of Endocrinology, Alma Mater Studiorum University of Bologna (UNIBO), Laboratoire de Génomique Biomédicale et Oncogénétique - Biomedical Genomics and Oncogenetics Laboratory (LR11IPT05), Université Tunis El Manar (UTM)-Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut Pasteur du Maroc, Réseau International des Instituts Pasteur (RIIP), Laboratoire de Biochimie Génétique, CHU de Bab El Oued-Université d'Alger 1, Intactile Design, Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Avignon Université (AU)-Université de La Réunion (UR)-Université de Montpellier (UM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Université de Tunis El Manar (UTM)-Institut Pasteur de Tunis, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Montpellier (UM)-Université Montpellier 1 (UM1), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université Tunis El Manar (UTM), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Male ,European People ,obesity ,Heredity ,Physiology ,[SDV]Life Sciences [q-bio] ,Gene Expression ,Biochemistry ,Settore MED/13 - Endocrinologia ,0302 clinical medicine ,Endocrinology ,Cell Signaling ,Medicine and Health Sciences ,Insulin ,Ethnicities ,ComputingMilieux_MISCELLANEOUS ,61 - Medicina ,Regulator gene ,2. Zero hunger ,Genetics ,Metabolic Syndrome ,Multidisciplinary ,Aminoacids ,human diet ,metabolism ,Middle Aged ,Genetic Mapping ,Romanian People ,Physiological Parameters ,Regulatory sequence ,Medicine ,Obesitat ,Female ,Genomic Signal Processing ,Research Article ,Signal Transduction ,Adult ,Protein Kinase C-alpha ,Haploview ,Science ,030209 endocrinology & metabolism ,Single-nucleotide polymorphism ,Nerve Tissue Proteins ,Biology ,Research and Analysis Methods ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,Insulin resistance ,Gene mapping ,medicine ,Humans ,Gene Regulation ,Molecular Biology Techniques ,Gene ,Molecular Biology ,Diabetic Endocrinology ,Insulinoresistència ,Endocrine Physiology ,Haplotype ,Gene Mapping ,Body Weight ,Biology and Life Sciences ,Cell Biology ,medicine.disease ,Hormones ,030104 developmental biology ,Amino Acid Transport Systems, Neutral ,Haplotypes ,People and Places ,Population Groupings ,Insulin Resistance ,Amino Acids, Branched-Chain - Abstract
International audience; Branched chain amino acids (BCAA) are essential elements of the human diet, which display increased plasma levels in obesity and regained particular interest as potential biomarkers for development of diabetes. To define determinants of insulin resistance (IR) we investigated 73 genes involved in BCAA metabolism or regulation by fine-scale haplotype mapping in two European populations with metabolic syndrome. French and Romanians (n = 465) were genotyped for SNPs (Affymetrix) and enriched by imputation (BEAGLE 4.1) at 1000 genome project density. Initial association hits detected by sliding window were refined (HAPLOVIEW 3.1 and PHASE 2.1) and correlated to homeostasis model assessment (HOMAIR) index, in vivo insulin sensitivity (SI) and BCAA plasma levels (ANOVA). Four genomic regions were associated with IR located downstream of MUT, AACS, SLC6A15 and PRKCA genes (P between 9.3 and 3.7 x 10-5). Inferred haplotypes up to 13 SNPs length were associated with IR (e.g. MUT gene with P < 4.9 x 10-5; Bonferroni 1.3 x 10-3) and synergistic to HOMAIR. SNPs in the same regions were also associated with one order of magnitude lower P values (e.g. rs20167284 in the MUT gene with P < 1.27 x 10-4) and replicated in Mediterranean samples (n = 832). In French, influential haplotypes (OR > 2.0) were correlated with in vivo insulin sensitivity (1/SI) except for SLC6A15 gene. Association of these genes with BCAA levels was variable, but influential haplotypes confirmed implication of MUT from BCAA metabolism as well as a role of regulatory genes (AACS and PRKCA) and suggested potential changes in transcriptional activity. These data drive attention towards new regulatory regions involved in IR in relation with BCAA and show the ability of haplotypes in phased DNA to detect signals complimentary to SNPs, which may be useful in designing genetic markers for clinical applications in ethnic populations.
- Published
- 2019
46. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- Author
-
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Joel Z Melnick, Michael G Miller, Pablo E Pergola, Vlado Perkovic, Sheldon Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw, Alicia Elbert, Augusto Vallejos, Andres Alvarisqueta, Laura Maffei, Luis Juncos, Javier de Arteaga, Gustavo Greloni, Eduardo Farias, Alfredo Zucchini, Daniel Vogel, Ana Cusumano, Juan Santos, Margaret Fraenkel, Martin Gallagher, Tim Davis, Shamasunder Acharya, Duncan Cooke, Michael Suranyi, Simon Roger, Nigel Toussaint, Carol Pollock, Doris Chan, Stephen Stranks, Richard MacIsaac, Zoltan Endre, Alice Schmidt, Rudolf Prager, Gert Mayer, Xavier Warling, Michel Jadoul, Jean Hougardy, Chris Vercammen, Bruno Van Vlem, Pieter Gillard, Adriana Costa e Forti, Joao Lindolfo Borges, Luis Santos Canani, Freddy Eliaschewitz, Silmara Leite, Fadlo Fraige Filho, Raphael Paschoalin, Jose Andrade Moura Neto, Luciane Deboni, Irene de Lourdes Noronha, Cintia Cercato, Carlos Alberto Prompt, Maria Zanella, Nelson Rassi, Domingos D'Avila, Rosangela Milagres, Joao Felicio, Roberto Pecoits Filho, Miguel Carlos Riella, Joao Salles, Elizete Keitel, Sergio Draibe, Celso Amodeo, Joseph Youmbissi, Louise Roy, Serge Cournoyer, Shivinder Jolly, Vincent Pichette, Gihad Nesrallah, Harpreet Singh Bajaj, Hasnain Khandwala, Ronnie Aronson, Richard Goluch, Paul Tam, Christian Rabbat, Gordon Bailey, Stephen Chow, Alvaro Castillo, Alfredo Danin Vargas, Fernando Gonzalez, Rodrigo Munoz, Vicente Gutierrez, Gonzalo Godoy, Hongwen Zhao, Zhangsuo Liu, Minghui Zhao, Xiaohui Guo, Benli Su, Shuxia Fu, Yan Xu, Jinkui Yang, Bingyin Shi, Guanqing Xiao, Wei Shi, Chuanming Hao, Changying Xing, Fanfan Hou, Qun Luo, Yuxiu Li, Linong Ji, Li Zuo, Song Wang, Zhaohui Ni, Guohua Ding, Nan Chen, Jiajun Zhao, Weiping Jia, Shengqiang Yu, Jian Weng, Gang Xu, Ping Fu, Shiren Sun, Bicheng Liu, Xiaoqiang Ding, Ivan Rychlik, Alexandra Oplustilova, Dagmar Bartaskova, Vaclava Honova, Hana Chmelickova, Martin Petr, Petr Bucek, Vladimir Tesar, Emil Zahumensky, Johan Povlsen, Kenneth Egstrup, Anna Oczachowska-Kulik, Peter Rossing, Jorma Lahtela, Jorma Strand, Ilkka Kantola, Catherine Petit, Christian Combe, Philippe Zaoui, Vincent Esnault, Pablo Urena Torres, Jean-Michel Halimi, Bertrand Dussol, Tasso Bieler, Klemens Budde, Frank Dellanna, Thomas Segiet, Christine Kosch, Hans Schmidt-Guertler, Isabelle Schenkenberger, Volker Vielhauer, Frank Pistrosch, Mark Alscher, Christoph Hasslacher, Christian Hugo, Anja Muehlfeld, Christoph Wanner, Ploumis Passadakis, Theofanis Apostolou, Nikolaos Tentolouris, Ioannis Stefanidis, Konstantinos Mavromatidis, Vasilios Liakopoulos, Dimitrios Goumenos, Konstantinos Siamopoulos, Vincent Yeung, Risa Ozaki, Samuel Fung, Kathryn Tan, Sydney Tang, Sing Leung Lui, Siu Fai Cheung, Seamus Sreenan, Joseph Eustace, Donal O'Shea, Peter Lavin, Austin Stack, Yoram Yagil, Julio Wainstein, Hilla Knobler, Josef Cohen, Irina Kenis, Deeb Daoud, Yosefa Bar-Dayan, Victor Frajewicki, Faiad Adawi, Loreto Gesualdo, Domenico Santoro, Francesco Marino, Andrea Galfre, Chiara Brunati, Piero Ruggenenti, Giuseppe Rombola, Giuseppe Pugliese, Maura Ravera, Fabio Malberti, Giuseppe Pontoriero, Teresa Rampino, Salvatore De Cosmo, Ciro Esposito, Felice Nappi, Cataldo Abaterusso, Giuseppe Conte, Vincenzo Panichi, Davide Lauro, Giovambattista Capasso, Domenico Russo, Jiichi Anzai, Motoji Naka, Keita Ato, Tetsuro Tsujimoto, Toshinori Nimura, Eitaro Nakashima, Tetsuro Takeda, Shinya Fujii, Kunihisa Kobayashi, Hideaki Iwaoka, Koji Nagayama, Hiroyuki Harada, Hajime Maeda, Rui Kishimoto, Tadashi Iitsuka, Naoki Itabashi, Ryuichi Furuya, Yoshitaka Maeda, Daishiro Yamada, Nobuhiro Sasaki, Hiromitsu Sasaki, Shinichiro Ueda, Naoki Kashihara, Shuichi Watanabe, Takehiro Nakamura, Hidetoshi Kanai, Yuichiro Makita, Keiko Ono, Noriyuki Iehara, Daisuke Goto, Keiichiro Kosuge, Kenichi Tsuchida, Toshiaki Sato, Takashi Sekikawa, Hideki Okamoto, Tsuyoshi Tanaka, Naoko Ikeda, Takenobu Tadika, Koji Mukasa, Takeshi Osonoi, Fuminori Hirano, Motonobu Nishimura, Yuko Yambe, Yukio Tanaka, Makoto Ujihara, Takashi Sakai, Mitsuo Imura, Yutaka Umayahara, Shinya Makino, Jun Nakazawa, Yukinari Yamaguchi, Susumu Kashine, Hiroaki Miyaoka, Katsunori Suzuki, Toshihiko Inoue, Sou Nagai, Nobuyuki Sato, Masahiro Yamamoto, Noriyasu Taya, Akira Fujita, Akira Matsutani, Yugo Shibagaki, Yuichi Sato, Akira Yamauchi, Masahiro Tsutsui, Tamayo Ishiko, Shizuka Kaneko, Nobuyuki Azuma, Hirofumi Matsuda, Yasuhiro Hashiguchi, Yukiko Onishi, Mikiya Tokui, Munehide Matsuhisa, Arihiro Kiyosue, Junji Shinoda, Kazuo Ishikawa, Ghazali Ahmad, Shalini Vijayasingham, Nor Azizah Aziz, Zanariah Hussein, Yin Khet Fung, Wan Hasnul Halimi Wan Hassan, Hin Seng Wong, Bak Leong Goh, Norhaliza Mohd Ali, Nor Shaffinaz Yusuf Azmi Merican, Indralingam Vaithilingam, Nik Nur Fatnoon Nik Ahmad, Noor Adam, Norlela Sukor, V Paranthaman P Vengadasalam, Khalid Abdul Kadir, Mafauzy Mohamed, Karina Renoirte Lopez, Aniceto Leguizamo-Dimas, Alfredo Chew Wong, Jose Chevaile-Ramos, Jose Gonzalez Gonzalez, Raul Rico Hernandez, Jose Nino-Cruz, Leobardo Sauque Reyna, Guillermo Gonzalez-Galvez, Magdalena Madero Rovalo, Tomasso Bochicchio-Ricardelli, Jorge Aldrete, Jaime Carranza-Madrigal, Liffert Vogt, Peter Smak Gregoor, JNM Barendregt, Peter Luik, Ronald Gansevoort, Gozewijn Laverman, Helen Pilmore, Helen Lunt, John Baker, Steven Miller, Kannaiyan Rabindranath, Luis Zapata-Rincon, Rolando Vargas-Gonzales, Jorge Calderon Ticona, Augusto Dextre Espinoza, Jose Burga Nunez, Carlos Antonio Zea-Nunez, Benjamin Herrada Orue, Boris Medina-Santander, Cesar Delgado-Butron, Julio Farfan-Aspilcueta, Stanislaw Mazur, Miroslaw Necki, Michal Wruk, Katarzyna Klodawska, Grazyna Popenda, Ewa Skokowska, Malgorzata Arciszewska, Andrzej Wiecek, Kazimierz Ciechanowski, Michal Nowicki, Rita Birne, Antonio Cabrita, Aura Ramos, Manuel Anibal Antunes Ferreira, Evelyn Matta Fontanet, Altagracia Aurora Alcantara-Gonzalez, Angel Comulada-Rivera, Eugenia Galindo Ramos, Jose Cangiano, Luis Quesada-Suarez, Ricardo Calderon Ortiz, Jose Vazquez-Tanus, Rafael Burgos-Calderon, Carlos Rosado, Nicolae Hancu, Ella Pintilei, Cristina Mistodie, Gabriel Bako, Lavinia Ionutiu, Ligia Petrica, Romulus Timar, Liliana Tuta, Livia Duma, Adriana Tutescu, Svetlana Ivanova, Ashot Essaian, Konstantin Zrazhevskiy, Natalia Tomilina, Elena Smolyarchuk, Anatoly Kuzin, Olga Lantseva, Irina Karpova, Minara Shamkhalova, Natalia Liberanskaya, Andrey Yavdosyuk, Yuri Shvarts, Tatiana Bardymova, Olga Blagoveshchenskaya, Oleg Solovev, Elena Rechkova, Natalia Pikalova, Maria Pavlova, Elena Kolmakova, Rustam Sayfutdinov, Svetlana Villevalde, Natalya Koziolova, Vladimir Martynenko, Vyacheslav Marasaev, Adelya Maksudova, Olga Sigitova, Viktor Mordovin, Vadim Klimontov, Yulia Samoylova, Tatiana Karonova, Lee Ying Yeoh, Boon Wee Teo, Marjorie Wai Yin Foo, Adrian Liew, Ivan Tkac, Aniko Oroszova, Jozef Fekete, Jaroslav Rosenberger, Ida Obetkova, Alla Fulopova, Eva Kolesarova, Katarina Raslova, Peter Smolko, Adrian Oksa, Larry Distiller, Julien Trokis, Luthando Adams, Hemant Makan, Padaruth Ramlachan, Essack Mitha, Kathleen Coetzee, Zelda Punt, Qasim Bhorat, Puvenesvari Naiker, Graham Ellis, Louis Van Zyl, Kwan Woo Lee, Min Seon Kim, Soon-Jib Yoo, Kun Ho Yoon, Yong-Wook Cho, Tae-Sun Park, Sang Yong Kim, Moon-Gi Choi, Tae Keun Oh, Kang-Wook Lee, Ho Sang Shon, Sung Hwan Suh, Byung-Joon Kim, Kim Doo-Man, Joo Hark Yi, Sang Ah Lee, Ho Chan Cho, Sin-Gon Kim, Dae-Ryong Cha, Ji A Seo, Kyung Mook Choi, Jeong-Taek Woo, Kyu Jeung Ahn, Jae Hyuk Lee, In-Joo Kim, Moon-Kyu Lee, Hak Chul Jang, Kyong-Soo Park, Beom Seok Kim, Ji Oh Mok, Mijung Shin, Sun Ae Yoon, Il-Seong Nam-Goong, Choon Hee Chung, Tae Yang Yu, Hyoung Woo Lee, Alfonso Soto Gonzalez, Jaume Almirall, Jesus Egido, Francesca Calero Gonzalez, Gema Fernandez Fresnedo, Ildefonso Valera Cortes, Manuel Praga Terente, Isabel Garcia Mendez, Juan Navarro Gonzalez, Jose Herrero Calvo, Secundino Cigarran Guldris, Mario Prieto Velasco, Jose Ignacio Minguela Pesquera, Antonio Galan, Julio Pascual, Maria Marques Vidas, Judith Martins Munoz, Jose Rodriguez-Perez, Cristina Castro-Alonso, Josep Bonet Sol, Daniel Seron, Elvira Fernandez Giraldez, Javier Arrieta Lezama, Nuria Montero, Julio Hernandez-Jaras, Rafael Santamaria Olmo, Jose Ramon Molas Coten, Olof Hellberg, Bengt Fellstrom, Andreas Bock, Dee Pei, Ching-Ling Lin, Kai-Jen Tien, Ching-Chu Chen, Chien-Ning Huang, Ju-Ying Jiang, Du-An Wu, Chih-Hsun Chu, Shih-Ting Tseng, Jung-Fu Chen, Cho-Tsan Bau, Wayne Sheu, Mai-Szu Wu, Ramazan Sari, Siren Sezer, Alaattin Yildiz, Ilhan Satman, Betul Kalender, Borys Mankovskyy, Ivan Fushtey, Mykola Stanislavchuk, Mykola Kolenyk, Iryna Dudar, Viktoriia Zolotaikina, Orest Abrahamovych, Tetyana Kostynenko, Olena Petrosyan, Petro Kuskalo, Olga Galushchak, Oleg Legun, Ivan Topchii, Liliya Martynyuk, Vasyl Stryzhak, Svitlana Panina, Sergii Tkach, Vadym Korpachev, Peter Maxwell, Luigi Gnudi, Sui Phin Kon, Hilary Tindall, Phillip Kalra, Patrick Mark, Dipesh Patel, Mohamed El-Shahawy, Liqun Bai, Romanita Nica, Yeong-Hau Lien, Judson Menefee, Robert Busch, Alan Miller, Azazuddin Ahmed, Ahmed Arif, Joseph Lee, Sachin Desai, Shweta Bansal, Marie Bentsianov, Mario Belledonne, Charles Jere, Raul Gaona, Gregory Greenwood, Osvaldo Brusco, Mark Boiskin, Diogo Belo, Raffi Minasian, Naveen Atray, Mary Lawrence, John Taliercio, Pablo Pergola, David Scott, German Alvarez, Bradley Marder, Thomas Powell, Wa'el Bakdash, George Stoica, Christopher McFadden, Marc Rendell, Jonathan Wise, Audrey Jones, Michael Jardula, Ivy-Joan Madu, Freemu Varghese, Brian Tulloch, Ziauddin Ahmed, Melanie Hames, Imran Nazeer, Newman Shahid, Rekha John, Manuel Montero, David Fitz-Patrick, Lawrence Phillips, Antonio Guasch, Elena Christofides, Aijaz Gundroo, Mohammad Amin, Cynthia Bowman-Stroud, Michael Link, Laura Mulloy, Michael Nammour, Tarik Lalwani, Lenita Hanson, Adam Whaley-Connell, Lee Herman, Rupi Chatha, Sayed Osama, Kenneth Liss, Zeid Kayali, Anuj Bhargava, Ezra Israel, Alfredo Peguero-Rivera, Michael Fang, Judith Slover, Elena Barengolts, Jose Flores, Rosemary Muoneke, Virginia Savin, Stella Awua-Larbi, Andrew Levine, George Newman, Laden Golestaneh, Guillermo Bohm, Efrain Reisin, Lucita Cruz, Robert Weiss, Franklin Zieve, Edward Horwitz, Peale Chuang, James Mersey, John Manley, Ronald Graf, Fadi Bedros, Sudhir Joshi, Juan Frias, Ali Assefi, Andrew O'Shaughnessy, Roman Brantley, Todd Minga, David Tietjen, Samuel Kantor, Aamir Jamal, Ramon Guadiz, Kenneth Hershon, Peter Bressler, Nelson Kopyt, Harold Cathcart, Scott Bloom, Ronald Reichel, Samer Nakhle, Emily Dulude, Joshua Tarkan, Penelope Baker, Steven Zeig, Jaynier Moya Hechevarria, Armando Ropero-Cartier, Gilda De la Calle, Ankur Doshi, Fadi Saba, Teresa Sligh, Sylvia Shaw, Jayant Kumar, Harold Szerlip, George Bayliss, Alan Perlman, Lakhi Sakhrani, Steven Gouge, Georges Argoud, Idalia Acosta, John Elder, Sucharit Joshi, John Sensenbrenner, Steven Vicks, Roberto Mangoo-Karim, Claude Galphin, Carlos Leon-Forero, John Gilbert, Eric Brown, Adeel Ijaz, Salman Butt, Mariana Markell, Carlos Arauz-Pacheco, Lance Sloan, Odilon Alvarado, Serge Jabbour, Eric Simon, Anjay Rastogi, Sam James, Karen Hall, John Melish, Brad Dixon, Allen Adolphe, Csaba Kovesdy, Srinivasan Beddhu, Richard Solomon, Ronald Fernando, Ellis Levin, Charuhas Thakar, Brooks Robey, David Goldfarb, Linda Fried, Geetha Maddukuri, Stephen Thomson, Andrew Annand, Saeed Kronfli, Paramjit Kalirao, Rebecca Schmidt, Neera Dahl, Samuel Blumenthal, Debra Weinstein, Ove Ostergaard, Talia Weinstein, Yasuhiro Ono, Murat Yalcin, Shahana Karim, APH - Health Behaviors & Chronic Diseases, Nephrology, ACS - Amsterdam Cardiovascular Sciences, ACS - Microcirculation, Biomedical Signals and Systems, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Heerspink, H. J. L., Parving, H. -H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F. -F., Kitzman, D. W., Kohan, D., Makino, H., Mcmurray, J. J. V., Melnick, J. Z., Miller, M. G., Pergola, P. E., Perkovic, V., Tobe, S., Yi, T., Wigderson, M., de Zeeuw, D., Elbert, A., Vallejos, A., Alvarisqueta, A., Maffei, L., Juncos, L., de Arteaga, J., Greloni, G., Farias, E., Zucchini, A., Vogel, D., Cusumano, A., Santos, J., Fraenkel, M., Gallagher, M., Davis, T., Acharya, S., Cooke, D., Suranyi, M., Roger, S., Toussaint, N., Pollock, C., Chan, D., Stranks, S., Macisaac, R., Endre, Z., Schmidt, A., Prager, R., Mayer, G., Warling, X., Jadoul, M., Hougardy, J., Vercammen, C., Van Vlem, B., Gillard, P., Costa e Forti, A., Borges, J. L., Santos Canani, L., Eliaschewitz, F., Leite, S., Fraige Filho, F., Paschoalin, R., Moura Neto, J. A., Deboni, L., de Lourdes Noronha, I., Cercato, C., Prompt, C. A., Zanella, M., Rassi, N., D'Avila, D., Milagres, R., Felicio, J., Pecoits Filho, R., Riella, M. C., Salles, J., Keitel, E., Draibe, S., Amodeo, C., Youmbissi, J., Roy, L., Cournoyer, S., Jolly, S., Pichette, V., Nesrallah, G., Bajaj, H. S., Khandwala, H., Aronson, R., Goluch, R., Tam, P., Rabbat, C., Bailey, G., Chow, S., Castillo, A., Danin Vargas, A., Gonzalez, F., Munoz, R., Gutierrez, V., Godoy, G., Zhao, H., Liu, Z., Zhao, M., Guo, X., Su, B., Fu, S., Xu, Y., Yang, J., Shi, B., Xiao, G., Shi, W., Hao, C., Xing, C., Hou, F., Luo, Q., Li, Y., Ji, L., Zuo, L., Wang, S., Ni, Z., Ding, G., Chen, N., Zhao, J., Jia, W., Yu, S., Weng, J., Xu, G., Fu, P., Sun, S., Liu, B., Ding, X., Rychlik, I., Oplustilova, A., Bartaskova, D., Honova, V., Chmelickova, H., Petr, M., Bucek, P., Tesar, V., Zahumensky, E., Povlsen, J., Egstrup, K., Oczachowska-Kulik, A., Rossing, P., Lahtela, J., Strand, J., Kantola, I., Petit, C., Combe, C., Zaoui, P., Esnault, V., Urena Torres, P., Halimi, J. -M., Dussol, B., Bieler, T., Budde, K., Dellanna, F., Segiet, T., Kosch, C., Schmidt-Guertler, H., Schenkenberger, I., Vielhauer, V., Pistrosch, F., Alscher, M., Hasslacher, C., Hugo, C., Muehlfeld, A., Wanner, C., Passadakis, P., Apostolou, T., Tentolouris, N., Stefanidis, I., Mavromatidis, K., Liakopoulos, V., Goumenos, D., Siamopoulos, K., Yeung, V., Ozaki, R., Fung, S., Tan, K., Tang, S., Lui, S. L., Cheung, S. F., Sreenan, S., Eustace, J., O'Shea, D., Lavin, P., Stack, A., Yagil, Y., Wainstein, J., Knobler, H., Cohen, J., Kenis, I., Daoud, D., Bar-Dayan, Y., Frajewicki, V., Adawi, F., Gesualdo, L., Santoro, D., Marino, F., Galfre, A., Brunati, C., Ruggenenti, P., Rombola, G., Pugliese, G., Ravera, M., Malberti, F., Pontoriero, G., Rampino, T., De Cosmo, S., Esposito, C., Nappi, F., Abaterusso, C., Conte, G., Panichi, V., Lauro, D., Capasso, G., Russo, D., Anzai, J., Naka, M., Ato, K., Tsujimoto, T., Nimura, T., Nakashima, E., Takeda, T., Fujii, S., Kobayashi, K., Iwaoka, H., Nagayama, K., Harada, H., Maeda, H., Kishimoto, R., Iitsuka, T., Itabashi, N., Furuya, R., Maeda, Y., Yamada, D., Sasaki, N., Sasaki, H., Ueda, S., Kashihara, N., Watanabe, S., Nakamura, T., Kanai, H., Makita, Y., Ono, K., Iehara, N., Goto, D., Kosuge, K., Tsuchida, K., Sato, T., Sekikawa, T., Okamoto, H., Tanaka, T., Ikeda, N., Tadika, T., Mukasa, K., Osonoi, T., Hirano, F., Nishimura, M., Yambe, Y., Tanaka, Y., Ujihara, M., Sakai, T., Imura, M., Umayahara, Y., Makino, S., Nakazawa, J., Yamaguchi, Y., Kashine, S., Miyaoka, H., Suzuki, K., Inoue, T., Nagai, S., Sato, N., Yamamoto, M., Taya, N., Fujita, A., Matsutani, A., Shibagaki, Y., Sato, Y., Yamauchi, A., Tsutsui, M., Ishiko, T., Kaneko, S., Azuma, N., Matsuda, H., Hashiguchi, Y., Onishi, Y., Tokui, M., Matsuhisa, M., Kiyosue, A., Shinoda, J., Ishikawa, K., Ahmad, G., Vijayasingham, S., Aziz, N. A., Hussein, Z., Fung, Y. K., Hassan, W. H. H. W., Wong, H. S., Goh, B. L., Ali, N. M., Merican, N. S. Y. A., Vaithilingam, I., Nik Ahmad, N. N. F., Adam, N., Sukor, N., Vengadasalam, V. P. P., Abdul Kadir, K., Mohamed, M., Renoirte Lopez, K., Leguizamo-Dimas, A., Chew Wong, A., Chevaile-Ramos, J., Gonzalez Gonzalez, J., Rico Hernandez, R., Nino-Cruz, J., Sauque Reyna, L., Gonzalez-Galvez, G., Madero Rovalo, M., Bochicchio-Ricardelli, T., Aldrete, J., Carranza-Madrigal, J., Vogt, L., Smak Gregoor, P., Barendregt, J. N. M., Luik, P., Gansevoort, R., Laverman, G., Pilmore, H., Lunt, H., Baker, J., Miller, S., Rabindranath, K., Zapata-Rincon, L., Vargas-Gonzales, R., Calderon Ticona, J., Dextre Espinoza, A., Burga Nunez, J., Zea-Nunez, C. A., Herrada Orue, B., Medina-Santander, B., Delgado-Butron, C., Farfan-Aspilcueta, J., Mazur, S., Necki, M., Wruk, M., Klodawska, K., Popenda, G., Skokowska, E., Arciszewska, M., Wiecek, A., Ciechanowski, K., Nowicki, M., Birne, R., Cabrita, A., Ramos, A., Antunes Ferreira, M. A., Matta Fontanet, E., Alcantara-Gonzalez, A. A., Comulada-Rivera, A., Galindo Ramos, E., Cangiano, J., Quesada-Suarez, L., Calderon Ortiz, R., Vazquez-Tanus, J., Burgos-Calderon, R., Rosado, C., Hancu, N., Pintilei, E., Mistodie, C., Bako, G., Ionutiu, L., Petrica, L., Timar, R., Tuta, L., Duma, L., Tutescu, A., Ivanova, S., Essaian, A., Zrazhevskiy, K., Tomilina, N., Smolyarchuk, E., Kuzin, A., Lantseva, O., Karpova, I., Shamkhalova, M., Liberanskaya, N., Yavdosyuk, A., Shvarts, Y., Bardymova, T., Blagoveshchenskaya, O., Solovev, O., Rechkova, E., Pikalova, N., Pavlova, M., Kolmakova, E., Sayfutdinov, R., Villevalde, S., Koziolova, N., Martynenko, V., Marasaev, V., Maksudova, A., Sigitova, O., Mordovin, V., Klimontov, V., Samoylova, Y., Karonova, T., Yeoh, L. Y., Teo, B. W., Foo, M. W. Y., Liew, A., Tkac, I., Oroszova, A., Fekete, J., Rosenberger, J., Obetkova, I., Fulopova, A., Kolesarova, E., Raslova, K., Smolko, P., Oksa, A., Distiller, L., Trokis, J., Adams, L., Makan, H., Ramlachan, P., Mitha, E., Coetzee, K., Punt, Z., Bhorat, Q., Naiker, P., Ellis, G., Van Zyl, L., Lee, K. W., Kim, M. S., Yoo, S. -J., Yoon, K. H., Cho, Y. -W., Park, T. -S., Kim, S. Y., Choi, M. -G., Oh, T. K., Lee, K. -W., Shon, H. S., Suh, S. H., Kim, B. -J., Doo-Man, K., Yi, J. H., Lee, S. A., Cho, H. C., Kim, S. -G., Cha, D. -R., Seo, J. A., Choi, K. M., Woo, J. -T., Ahn, K. J., Lee, J. H., Kim, I. -J., Lee, M. -K., Jang, H. C., Park, K. -S., Kim, B. S., Mok, J. O., Shin, M., Yoon, S. A., Nam-Goong, I. -S., Chung, C. H., Yu, T. Y., Lee, H. W., Soto Gonzalez, A., Almirall, J., Egido, J., Calero Gonzalez, F., Fernandez Fresnedo, G., Valera Cortes, I., Praga Terente, M., Garcia Mendez, I., Navarro Gonzalez, J., Herrero Calvo, J., Cigarran Guldris, S., Prieto Velasco, M., Minguela Pesquera, J. I., Galan, A., Pascual, J., Marques Vidas, M., Martins Munoz, J., Rodriguez-Perez, J., Castro-Alonso, C., Bonet Sol, J., Seron, D., Fernandez Giraldez, E., Arrieta Lezama, J., Montero, N., Hernandez-Jaras, J., Santamaria Olmo, R., Molas Coten, J. R., Hellberg, O., Fellstrom, B., Bock, A., Pei, D., Lin, C. -L., Tien, K. -J., Chen, C. -C., Huang, C. -N., Jiang, J. -Y., Wu, D. -A., Chu, C. -H., Tseng, S. -T., Chen, J. -F., Bau, C. -T., Sheu, W., Wu, M. -S., Sari, R., Sezer, S., Yildiz, A., Satman, I., Kalender, B., Mankovskyy, B., Fushtey, I., Stanislavchuk, M., Kolenyk, M., Dudar, I., Zolotaikina, V., Abrahamovych, O., Kostynenko, T., Petrosyan, O., Kuskalo, P., Galushchak, O., Legun, O., Topchii, I., Martynyuk, L., Stryzhak, V., Panina, S., Tkach, S., Korpachev, V., Maxwell, P., Gnudi, L., Kon, S. P., Tindall, H., Kalra, P., Mark, P., Patel, D., El-Shahawy, M., Bai, L., Nica, R., Lien, Y. -H., Menefee, J., Busch, R., Miller, A., Ahmed, A., Arif, A., Lee, J., Desai, S., Bansal, S., Bentsianov, M., Belledonne, M., Jere, C., Gaona, R., Greenwood, G., Brusco, O., Boiskin, M., Belo, D., Minasian, R., Atray, N., Lawrence, M., Taliercio, J., Pergola, P., Scott, D., Alvarez, G., Marder, B., Powell, T., Bakdash, W., Stoica, G., Mcfadden, C., Rendell, M., Wise, J., Jones, A., Jardula, M., Madu, I. -J., Varghese, F., Tulloch, B., Ahmed, Z., Hames, M., Nazeer, I., Shahid, N., John, R., Montero, M., Fitz-Patrick, D., Phillips, L., Guasch, A., Christofides, E., Gundroo, A., Amin, M., Bowman-Stroud, C., Link, M., Mulloy, L., Nammour, M., Lalwani, T., Hanson, L., Whaley-Connell, A., Herman, L., Chatha, R., Osama, S., Liss, K., Kayali, Z., Bhargava, A., Israel, E., Peguero-Rivera, A., Fang, M., Slover, J., Barengolts, E., Flores, J., Muoneke, R., Savin, V., Awua-Larbi, S., Levine, A., Newman, G., Golestaneh, L., Bohm, G., Reisin, E., Cruz, L., Weiss, R., Zieve, F., Horwitz, E., Chuang, P., Mersey, J., Manley, J., Graf, R., Bedros, F., Joshi, S., Frias, J., Assefi, A., O'Shaughnessy, A., Brantley, R., Minga, T., Tietjen, D., Kantor, S., Jamal, A., Guadiz, R., Hershon, K., Bressler, P., Kopyt, N., Cathcart, H., Bloom, S., Reichel, R., Nakhle, S., Dulude, E., Tarkan, J., Baker, P., Zeig, S., Moya Hechevarria, J., Ropero-Cartier, A., De la Calle, G., Doshi, A., Saba, F., Sligh, T., Shaw, S., Kumar, J., Szerlip, H., Bayliss, G., Perlman, A., Sakhrani, L., Gouge, S., Argoud, G., Acosta, I., Elder, J., Sensenbrenner, J., Vicks, S., Mangoo-Karim, R., Galphin, C., Leon-Forero, C., Gilbert, J., Brown, E., Ijaz, A., Butt, S., Markell, M., Arauz-Pacheco, C., Sloan, L., Alvarado, O., Jabbour, S., Simon, E., Rastogi, A., James, S., Hall, K., Melish, J., Dixon, B., Adolphe, A., Kovesdy, C., Beddhu, S., Solomon, R., Fernando, R., Levin, E., Thakar, C., Robey, B., Goldfarb, D., Fried, L., Maddukuri, G., Thomson, S., Annand, A., Kronfli, S., Kalirao, P., Schmidt, R., Dahl, N., Blumenthal, S., Weinstein, D., Ostergaard, O., Weinstein, T., Ono, Y., Yalcin, M., Karim, S., Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, and Diabetes Clinic
- Subjects
Male ,endothelin ,albuminuria ,nephropathy ,inhibition ,Diabetes Mellitus, Type 2/drug therapy ,Endocrinology, Diabetes and Metabolism ,Placebo-controlled study ,Administration, Oral ,030204 cardiovascular system & hematology ,Settore MED/13 - Endocrinologia ,chemistry.chemical_compound ,0302 clinical medicine ,ENDOTHELIN ,80 and over ,Diabetic Nephropathies ,030212 general & internal medicine ,Renal Insufficiency ,Chronic ,Aged, 80 and over ,Diabetic Nephropathies/blood ,General Medicine ,Middle Aged ,Atrasentan/administration & dosage ,Editorial Commentary ,Treatment Outcome ,Nephrology ,Creatinine ,Administration ,young adult ,Female ,medicine.symptom ,Glomerular filtration rate ,Type 2 ,Endothelin A Receptor Antagonists/administration & dosage ,medicine.drug ,Glomerular Filtration Rate ,Human ,Oral ,Adult ,medicine.medical_specialty ,ALBUMINURIA ,Endothelin A Receptor Antagonists ,NEPHROPATHY ,Urology ,INHIBITION ,Renal function ,Serum Albumin, Human ,Placebo ,Nephropathy ,03 medical and health sciences ,Young Adult ,Double-Blind Method ,Atresentan ,diabetes, chronic kidney disease ,medicine ,Diabetes Mellitus ,Aged ,Atrasentan ,Diabetes Mellitus, Type 2 ,Humans ,Renal Insufficiency, Chronic ,Serum Albumin ,business.industry ,Creatinine/blood ,medicine.disease ,Serum Albumin, Human/urine ,n/a OA procedure ,chemistry ,Albuminuria ,Renal Insufficiency, Chronic/blood ,business ,aged, 80 and over ,Kidney disease - Abstract
Background Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.Methods We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1.73 m(2) of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g who had received maximum labelled or tolerated renin-angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0.75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0.75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for >= 30 days) or end-stage kidney disease (eGFR = 90 days, chronic dialysis for >= 90 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials. gov, number NCT01858532.Findings Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2.2 years (IQR 1.4-2.9). 79 (6.0%) of 1325 patients in the atrasentan group and 105 (7.9%) of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR] 0.65 [95% CI 0.49-0.88]; p=0.0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3.5%) of 1325 patients in the atrasentan group and 34 (2.6%) of 1323 patients in the placebo group (HR 1.33 [95% CI 0.85-2.07]; p=0.208). 58 (4.4%) patients in the atrasentan group and 52 (3.9%) in the placebo group died (HR 1.09 [95% CI 0.75-1.59]; p=0.65).Interpretation Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
- Published
- 2019
47. [Temporal changes in the epidemiology of diabetes mellitus in Turkey: A systematic review and meta-analysis]
- Author
-
Cem Barçın, Fahri Bayram, Doruk Karaaslan, Ilhan Satman, Necla Ozer, Mustafa Kılıçkap, Mahmut Şahin, Gultekin Suleymanlar, Lale Tokgozoglu, Hüseyin Göksülük, Mehmet Yilmaz, Adnan Abaci, and Meral Kayıkçıoğlu
- Subjects
epidemiology ,meta analysis ,prevalence ,lcsh:Internal medicine ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Turkish population ,medicine.medical_specialty ,Turkey ,MEDLINE ,lcsh:Medicine ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Diabetes mellitus ,Epidemiology ,medicine ,Prevalence ,Humans ,Meta-regression ,030212 general & internal medicine ,Temporal change ,lcsh:RC31-1245 ,business.industry ,Public health ,lcsh:R ,Regression analysis ,medicine.disease ,Random effects model ,Blood pressure ,Diabetes Mellitus, Type 2 ,lcsh:RC666-701 ,Meta-analysis ,diabetes mellitus ,Cardiology and Cardiovascular Medicine ,business ,Demography - Abstract
Objective Diabetes mellitus (DM) is a serious public health problem. Despite various epidemiological studies reporting prevalence of DM in Turkey, there is no meta-analysis or systematic review evaluating these studies as a whole and assessing temporal changes in the prevalence of DM. In this meta-analysis, the studies that have been conducted in the last 15 years and which provide information on the prevalence of DM in our country are examined. Methods Epidemiological studies on cardiovascular risk factors in adult Turkish population that had been conducted within the last 15 years and having the capacity of either representating or potentially representing the country, were searched through Ovid, Medline and Web of Science Core Collection the Turkish Academic Network and Information Center (ULAKBIM) databases. Additionally, websites of Ministry of Health and related societies were investigated for additional studies. Random effects model was used in meta-analysis of low bias risk studies. Meta-regression was performed to evaluate the temporal change in DM prevalence. Results There were 8 studies which provided information with regard to DM prevalence (n=84656). Four of these studies (n=56853) had low bias risk and four had high bias risk (n=27803). When compared with low bias risk studies, those with high bias risk had very large variation of DM prevalence (between 4% to 15%). Meta-analysis of the low bias risk group yielded a crude DM prevalence of 13.5% (95% CI: 11.6-15.5%) in the whole group, 14.2% (95% CI: 12.3-16.2%) in females, 12.6% (95% CI: 10.5-14.9%) in males. In meta-regression analysis of low bias risk group, mean age difference among the studies and the time period in which the study was undertaken were partially able to explain the inter-study heterogeneity (R2 values were 52% and 78%). Conclusion This meta-analysis shows that DM is a highly prevalent public health problem in our country. Contrary to studies, which compare the recent studies with previous ones and report an increasing prevalence of DM, the present meta-analysis-despite its limitations-provides findings that the temporal increase of DM prevalence is at least paused over time. This situation underlines the need for new studies.
- Published
- 2018
48. Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul
- Author
-
Tevfik Demir, Ilhan Satman, Rifat Emral, Cem Haymana, Murat Caglayan, Ilker Tasci, Kazim Yalcin Arga, Erman Cakal, Derun Taner Ertugrul, Serpil Salman, Alper Sonmez, Naim Ata, Ibrahim Demirci, Ibrahim Sahin, Aysegul Atmaca, Ugur Unluturk, Osman Celik, Mustafa Sahin, Selcuk Dagdelen, Satman, Ilhan, Demirci, Ibrahim, Haymana, Cem, Tasci, Ilker, Salman, Serpil, Ata, Naim, Dagdelen, Selcuk, Sahin, Ibrahim, Emral, Rifat, Cakal, Erman, Atmaca, Aysegul, Sahin, Mustafa, Celik, Osman, Demir, Tevfik, Ertugrul, Derun, Unluturk, Ugur, Arga, Kazim Yalcin, Caglayan, Murat, and Sonmez, Alper
- Subjects
PNEUMONIA ,ICD-10, International Classification of Diseases-10 ,Male ,Turkey ,type 2 diabetes mellitus ,Endocrinology, Diabetes and Metabolism ,HbA1c, Glycosylated hemoglobin A1c ,Type 2 diabetes ,DISEASE ,CAD, Coronary artery disease ,ULN, Upper limit of normal ,0302 clinical medicine ,Endocrinology ,CLINICAL CHARACTERISTICS ,Risk Factors ,Medicine ,CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration ,030212 general & internal medicine ,Istanbul ,T2DM, Type 2 diabetes mellitus ,COVID-19, Coronavirus disease 2019 ,education.field_of_study ,Mortality rate ,General Medicine ,Middle Aged ,HDL-chol, High density lipoprotein cholesterol ,CRP, C-reactive protein ,CT, Computed tomography ,Female ,CVD, Cardiovascular diseases (including coronary artery disease, peripheral artery disease, and stroke) ,Non-DM, Non diabetes mellitus ,AST, Aspartate aminotransferase ,SPSS, Statistical Package for the Social Sciences ,hospitalization ,PSM, Propensity Score Matching system ,LDL-chol, Low density lipoprotein cholesterol ,Adult ,medicine.medical_specialty ,AHD, Antihyperglycemic drugs ,Population ,COPD, Chronic obstructive pulmonary disease ,030209 endocrinology & metabolism ,BMI, Body mass index ,Article ,CI, Confidence intervals ,03 medical and health sciences ,ICU, Intensive Care Unit ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,Humans ,COHORT ,Risk factor ,education ,Retrospective Studies ,eGFR, Estimated glomerular filtration rate ,LDH, Lactate dehydrogenase ,SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 ,business.industry ,ALT, Alanine aminotransferase ,ASA, Acetylsalicylic acid ,COVID-19 ,Type 2 Diabetes Mellitus ,Retrospective cohort study ,IQR, Interquartile range ,rt-PCR, Reverse transcription-polymerase chain reaction ,medicine.disease ,mortality ,Survival Analysis ,LMWH, Low molecular weight heparin ,CKD, Chronic kidney disease ,Diabetes Mellitus, Type 2 ,Propensity score matching ,MoH, Ministry of Health ,business ,OR, Odds ratio - Abstract
Aims: Type 2 diabetes mellitus (T2DM) is a risk factor for severe COVID-19. Our aim was to compare the clinical outcomes of patients with and without T2DM during the first hit of COVID-19 in Istanbul.& nbsp; Methods: A retrospective population-based study was conducted including all consecutive adult symptomatic COVID-19 cases. Patients were confirmed with rt-PCR; treated and monitored in accordance with standard protocols. The primary endpoints were hospitalization and 30-day mortality.& nbsp; Results: Of the 93,571 patients, 22.6% had T2DM, with older age and higher BMI. Propensity Score matched evaluation resulted in significantly higher rates of hospitalization (1.5-fold), 30-day mortality (1.6-fold), and pneumonia (1.4-fold). They revealed more severe laboratory deviations, comorbidities, and frequent drug usage than the Non-DM group. In T2DM age, pneumonia, hypertension, obesity, and insulin-based therapies were associated with an increased likelihood of hospitalization; whereas age, male gender, lymphopenia, obesity, and insulin treatment were considerably associated with higher odds of death.& nbsp; Conclusions: COVID-19 patients with T2DM had worse clinical outcomes with higher hospitalization and 30-day mortality rates than those without diabetes. Compared to most territories of the world, COVID-19 mortality was much lower in Istanbul, which may be associated with accessible healthcare provision and the younger structure of the population.& nbsp; (C)& nbsp;2021 Elsevier B.V. All rights reserved.
- Published
- 2021
49. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
- Author
-
Caner Arslan, Turan Aslan, Oral Oncul, Onder Kilicoglu, Irfan Sencan, Selcuk Baktiroglu, Ilhan Satman, Selda Celik, Lutfiye Mulazimoglu, Zeynep Osar-Siva, Ayten Kadanali, Abdullah Kemal Tuygun, Ali Oznur, Muzaffer Altindas, Ahmet Cinar Yasti, Özge Turhan, Bulent Ertugrul, Temel Yilmaz, Aynur Engin, Haluk Eraksoy, Serdar Güler, Onder Ergonul, Ozlem Tanriover, Nese Saltoglu, Şamil Aktaş, Hasan Tüzün, and Nermin Olgun
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,business.industry ,Turkish ,030209 endocrinology & metabolism ,medicine.disease ,Diabetic foot ,language.human_language ,Surgery ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Diagnosis treatment ,Internal medicine ,language ,Medicine ,business ,Turkish Consensus Report-, KLIMIK JOURNAL, cilt.28, ss.2-34, 2015 [SALTOĞLU N., Kilicoglu O., Baktiroglu S., Osar-Siva Z., AKTAŞ Ş., Altindas M., Arslan C., Aslan T., Celik S., Engin A., et al., -Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections] - Abstract
Study Group for Diabetic Foot Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases has called for collaboration of the relevant specialist societies and the Ministry of Health to issue a national consensus report on the diagnosis, treatment and prevention of diabetic foot (DF) wounds and diabetic foot infections (DFIs) in Turkey. In the periodical meetings of the assigned representatives from all the parties, various questions as to pathogenesis, microbiology, assessment and grading, treatment, prevention and control of diabetic foot were identified. Upon reviewing related literature and international guidelines, these questions were provided with consensus answers. Several of the answers provided in the report are listed below: [1] Although there are many reasons for the development of DF wounds, the main reason is the combined effect of diabetes-related vascular disease and neuropathy. [2] Aerobic Gram- positive cocci are mostly responsible for superficial DFIs in patients with cellulitis and no history of antibiotic use. [3] Pseudomonas aeruginosa is one of the commonly encountered agents when between the toes of the patient are moist. [4] When the other potential reasons are eliminated, DFIs should be considered in presence of at least two of the classical signs of inflammation including redness, warmth, swelling, tenderness, and pain, or purulent discharge in the foot lesion. [5] Infections are classified into mild, moderate, or severe groups according to some criteria such as the depth and width of the wounds, and the presence of systemic findings of infection. [6] PEDIS system should be preferred as a classification system for its high predictive value in diabetes-related foot complications. [7] Culture samples from the DF wound should only be obtained when infection is clinically considered and, where possible, before starting antibiotic treatment. [8] Inflammatory biomarkers such as leukocyte count, C-reactive protein, erythrocyte sedimentation rate, and procalcitonin may be useful in distinguishing between colonization with infection. [9] Magnetic resonance imaging is a sensitive and specific method in patients unresponsive to treatment when osteomyelitis and deep soft tissue abscesses are considered. [10] The gold standard in the diagnosis of osteomyelitis is histopathological examination. [11] To provide wound healing and to save the limb, removal of dead and infected tissue with urgent and aggressive debridement, appropriate antibiotic therapy, metabolic control, and off-loading of pressure, the diagnosis and proper treatment of peripheral arterial disease, and restoration of the foot function are necessary. [12] A lot of different factors playing a role in etiopathogenesis complicate the approach to be developed in this type of lesions, and therefore it requires a team concept. [13] In the empirical treatment, the objective should be treating only the potential agents. Adequate tissue levels, low side effects and patient compliance must be observed; effective drugs should be used in specified doses and duration. [14] Debridement is an essential and integral part of wound treatment and is an important tool allowing the formation of healthy granulation tissue. [15] When the infected tissue cannot be completely cleared with the debridement and in cases when the patient could not cope with the remaining infection load, performing a limb amputation on a safe level of infection would be lifesaving.
- Published
- 2016
50. A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria
- Author
-
Ilhan Satman, Beyhan Omer, Jaakko Tuomilehto, Halim Issever, Kubilay Karsidag, Selda Celik, Sema Genc, Nevin Dinccag, Aysegul Telci, and Yildiz Tutuncu
- Subjects
Blood Glucose ,Male ,Time Factors ,Turkey ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,030204 cardiovascular system & hematology ,Bioinformatics ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Gastroenterology ,0302 clinical medicine ,Endocrinology ,Oral glucose tolerance ,Response rate (survey) ,Glucose tolerance test ,education.field_of_study ,medicine.diagnostic_test ,biology ,Fasting ,Middle Aged ,3. Good health ,C-Reactive Protein ,Area Under Curve ,Predictive value of tests ,Female ,Research Article ,Adult ,medicine.medical_specialty ,Article Subject ,Population ,030209 endocrinology & metabolism ,03 medical and health sciences ,Predictive Value of Tests ,Diabetes mellitus ,Internal medicine ,Diabetes Mellitus ,medicine ,Humans ,education ,Glycated Hemoglobin ,lcsh:RC648-665 ,business.industry ,C-reactive protein ,Reproducibility of Results ,nutritional and metabolic diseases ,Glucose Tolerance Test ,medicine.disease ,ROC Curve ,biology.protein ,Hemoglobin ,business ,Biomarkers - Abstract
Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) have been used to diagnose new-onset diabetes mellitus (DM) in order to simplify the diagnostic tests compared with the 2-hour oral glucose tolerance test (OGTT; 2-hPG). We aimed to identify optimal cut-off points of high sensitive C-reactive protein (hs-CRP) in new-onset DM people based on FPG, 2-hPG, or HbA1c methods. Data derived from recent population-based survey in Turkey (TURDEP-II). The study included 26,499 adult people (63% women, response rate 85%). The mean serum concentration of hs-CRP in women was higher than in men (p<0.001). The people with new-onset DM based on HbA1c had higher mean hs-CRP level than FPG based and 2-hPG based DM cases. In HbA1c, 2-hPG, and FPG based new-onset DM people, cut-off levels of hs-CRP in women were 2.9, 2.1, and 2.5 mg/L [27.5, 19.7, and 23.5 nmol/L] and corresponding values in men were 2.0, 1.8, and 1.8 mg/L (19.0, 16.9, and 16.9 nmol/L), respectively (sensitivity 60–65% and specificity 54–64%). Our results revealed that hs-CRP may not further strengthen the diagnosis of new-onset DM. Nevertheless, the highest hs-CRP level observed in new-onset DM people diagnosed with HbA1c criterion supports the general assumption that this method might recognize people in more advanced diabetic stage compared with other diagnostic methods.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.